https://trial.medpath.com/news/at-19-by-shanghai-yake-biotechnology-for-follicular-lymphoma-likelihood-of-approval 2025-01-01T00:26:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/at-19-by-shanghai-yake-biotechnology-for-follicular-lymphoma-likelihood-of-approval 2025-01-01T00:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/top-5-most-read-articles-on-myasthenia-gravis-in-2024 2025-01-01T00:22:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/top-5-most-read-articles-on-myasthenia-gravis-in-2024 2025-01-01T00:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-announces-business-and-pipeline-updates-at-j-p-morgan-healthcare-conference 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-announces-business-and-pipeline-updates-at-j-p-morgan-healthcare-conference 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nivolumab-shows-promise-in-refractory-biliary-tract-cancer-with-22-response-rate-in-phase-ii-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nivolumab-shows-promise-in-refractory-biliary-tract-cancer-with-22-response-rate-in-phase-ii-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-sciences-announces-11-billion-investment-in-us-drug-manufacturing-expansion 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-sciences-announces-11-billion-investment-in-us-drug-manufacturing-expansion 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-asset-purchase-deals-show-sustained-growth-since-2019-report-reveals 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-asset-purchase-deals-show-sustained-growth-since-2019-report-reveals 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/itepekimab-met-the-primary-endpoint-in-one-of-two-copd-phase-3 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itepekimab-met-the-primary-endpoint-in-one-of-two-copd-phase-3 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/visugromab-plus-nivolumab-shows-promise-in-anti-pd-1-refractory-solid-tumors-by-targeting-gdf-15-pathway 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/visugromab-plus-nivolumab-shows-promise-in-anti-pd-1-refractory-solid-tumors-by-targeting-gdf-15-pathway 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-update-to-18-year-guidance-on-developing-biologics-biosimilars-and-vaccines 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-proposes-update-to-18-year-guidance-on-developing-biologics-biosimilars-and-vaccines 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/doxorubicin-plus-pembrolizumab-shows-promise-in-phase-2-trial-for-advanced-soft-tissue-sarcoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doxorubicin-plus-pembrolizumab-shows-promise-in-phase-2-trial-for-advanced-soft-tissue-sarcoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-cognition-s-oral-therapy-zunveyl-r-receives-fda-approval-to-treat 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-cognition-s-oral-therapy-zunveyl-r-receives-fda-approval-to-treat 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a-new-horizon-in-alzheimers-disease-targeting-highly-neurotoxic-amyloid-b-oligomers-abos 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-new-horizon-in-alzheimers-disease-targeting-highly-neurotoxic-amyloid-b-oligomers-abos 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a-phase-1-study-of-tyra-300-in-people-with-advanced 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-phase-1-study-of-tyra-300-in-people-with-advanced 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-s-brukinsa-approved-by-swissmedic-for-waldenstroms-macroglobulinemia-treatment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-s-brukinsa-approved-by-swissmedic-for-waldenstroms-macroglobulinemia-treatment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/an-efficacy-and-safety-study-of-rpt193-in-adults-with-atopic 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/an-efficacy-and-safety-study-of-rpt193-in-adults-with-atopic 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-on-inhaled-fexlamose-for-treating-moderate-to-severe-copd-in-adults 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-on-inhaled-fexlamose-for-treating-moderate-to-severe-copd-in-adults 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/recce-pharmaceuticals-secures-strategic-patent-protection-in-china-for-antimicrobial-technology 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recce-pharmaceuticals-secures-strategic-patent-protection-in-china-for-antimicrobial-technology 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ionis-reports-positive-phase-3-results-for-olezarsen-in-familial-chylomicronemia-syndrome 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionis-reports-positive-phase-3-results-for-olezarsen-in-familial-chylomicronemia-syndrome 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/upc-rejects-boehringer-ingelheim-s-preliminary-injunction-against-zentiva-s-generic-nintedanib 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upc-rejects-boehringer-ingelheim-s-preliminary-injunction-against-zentiva-s-generic-nintedanib 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-gsk-s-nucala-for-copd-treatment-expanding-therapeutic-options 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-gsk-s-nucala-for-copd-treatment-expanding-therapeutic-options 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scisparc-secures-japanese-patent-for-pain-relief-combo-by-x 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scisparc-secures-japanese-patent-for-pain-relief-combo-by-x 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-issues-positive-opinion-on-poltreg-s-pediatric-investigation-plan-for-type-1-diabetes-treg-therapy 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-issues-positive-opinion-on-poltreg-s-pediatric-investigation-plan-for-type-1-diabetes-treg-therapy 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/compass-pathways-psilocybin-drug-meets-primary-endpoint-in-phase-3-trial-despite-market-disappointment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-pathways-psilocybin-drug-meets-primary-endpoint-in-phase-3-trial-despite-market-disappointment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-deputy-commissioner-signals-potential-reforms-to-pdufa-program 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-deputy-commissioner-signals-potential-reforms-to-pdufa-program 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-cancer-institute-launches-phase-ii-trials-testing-immunotherapy-in-meningioma-and-melanoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-cancer-institute-launches-phase-ii-trials-testing-immunotherapy-in-meningioma-and-melanoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cytomx-therapeutics-initiates-combination-therapy-arm-in-phase-1-melanoma-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomx-therapeutics-initiates-combination-therapy-arm-in-phase-1-melanoma-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/arch-biopartners-announces-financing-and-clinical-trial-progress 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arch-biopartners-announces-financing-and-clinical-trial-progress 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-launches-global-phase-2-trial-of-zanubrutinib-for-relapsed-or-refractory-marginal-zone-lymphoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-launches-global-phase-2-trial-of-zanubrutinib-for-relapsed-or-refractory-marginal-zone-lymphoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/schizophrenia-today-what-s-new-and-what-s-coming 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schizophrenia-today-what-s-new-and-what-s-coming 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/circassia-receives-fda-boost-for-copd-drugs-in-the-us 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circassia-receives-fda-boost-for-copd-drugs-in-the-us 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-human-trial-finds-a-dopamine-continuous-intracerebroventricular 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-human-trial-finds-a-dopamine-continuous-intracerebroventricular 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a-real-world-study-to-gain-clinical-insights-into-faricimab-fareal-study 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-real-world-study-to-gain-clinical-insights-into-faricimab-fareal-study 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-iteos-halt-development-of-tigit-immunotherapy-after-failed-lung-cancer-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-and-iteos-halt-development-of-tigit-immunotherapy-after-failed-lung-cancer-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/systimmune-to-present-updated-izalontamab-brengitecan-data-for-her2-negative-breast-cancer-at-esmo-breast-2025 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systimmune-to-present-updated-izalontamab-brengitecan-data-for-her2-negative-breast-cancer-at-esmo-breast-2025 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/intensified-total-neoadjuvant-therapy-in-patients-with 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensified-total-neoadjuvant-therapy-in-patients-with 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bladder-tumor-focused-adaptive-radiotherapy-clinical-outcomes-and-feasibility 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bladder-tumor-focused-adaptive-radiotherapy-clinical-outcomes-and-feasibility 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-s-brukinsa-receives-european-commission-approval-for-cll-treatment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-s-brukinsa-receives-european-commission-approval-for-cll-treatment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-in-antibiotic-development-for-gram-negative-bacteria 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-in-antibiotic-development-for-gram-negative-bacteria 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-announces-positive-phase-3-trial-results-for-tislelizumab-in-nasopharyngeal-cancer 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-announces-positive-phase-3-trial-results-for-tislelizumab-in-nasopharyngeal-cancer 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/two-phase-iii-trials-target-advanced-breast-cancer-with-novel-therapeutic-approaches 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-phase-iii-trials-target-advanced-breast-cancer-with-novel-therapeutic-approaches 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-study-of-tti-101-for-advanced-liver-cancer-patients 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-study-of-tti-101-for-advanced-liver-cancer-patients 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-tests-yoga-as-non-pharmacological-treatment-for-chemotherapy-induced-peripheral-neuropathy 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trial-tests-yoga-as-non-pharmacological-treatment-for-chemotherapy-induced-peripheral-neuropathy 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-evaluates-new-treatment-for-non-healing-diabetic-foot-ulcers 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-evaluates-new-treatment-for-non-healing-diabetic-foot-ulcers 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-to-acquire-23andme-for-310-million-gaining-access-to-vast-genetic-database 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-to-acquire-23andme-for-310-million-gaining-access-to-vast-genetic-database 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scienture-secures-fda-orange-book-patent-listing-for-arblitm-losartan-potassium-oral-suspension 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scienture-secures-fda-orange-book-patent-listing-for-arblitm-losartan-potassium-oral-suspension 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aerpio-initiates-phase-2-trial-of-razuprotafib-for-covid-19-blood-vessel-damage 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aerpio-initiates-phase-2-trial-of-razuprotafib-for-covid-19-blood-vessel-damage 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abeona-therapeutics-sells-priority-review-voucher-as-nppa-sets-prices-for-84-new-drugs 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abeona-therapeutics-sells-priority-review-voucher-as-nppa-sets-prices-for-84-new-drugs 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-upar-targeting-imaging-agent-fg001-shows-promise-in-oral-and-oropharyngeal-cancer-surgery 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-upar-targeting-imaging-agent-fg001-shows-promise-in-oral-and-oropharyngeal-cancer-surgery 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-moves-antibiotic-against-superbug-into-phase-3-of-testing-x 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-moves-antibiotic-against-superbug-into-phase-3-of-testing-x 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-clinical-trials-review-on-friedreich-ataxia-for-2024 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-clinical-trials-review-on-friedreich-ataxia-for-2024 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-initiates-phase-i-clinical-trial-of-bgb-a317-in-china 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-initiates-phase-i-clinical-trial-of-bgb-a317-in-china 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-directs-covid-19-vaccine-manufacturers-to-update-formulations-for-fall-2024 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-directs-covid-19-vaccine-manufacturers-to-update-formulations-for-fall-2024 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-teal-health-s-at-home-hpv-test-expanding-cervical-cancer-screening-access 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-teal-health-s-at-home-hpv-test-expanding-cervical-cancer-screening-access 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-advances-v181-quadrivalent-dengue-vaccine-candidate-toward-june-2025-milestone 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-advances-v181-quadrivalent-dengue-vaccine-candidate-toward-june-2025-milestone 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/actuate-therapeutics-reports-significant-survival-improvement-in-metastatic-pancreatic-cancer-phase-2-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actuate-therapeutics-reports-significant-survival-improvement-in-metastatic-pancreatic-cancer-phase-2-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-human-study-for-resistant-epilepsy-using-vagus-nerve-stimulation-device 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-human-study-for-resistant-epilepsy-using-vagus-nerve-stimulation-device 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-compares-proton-therapy-to-standard-radiation-for-leptomeningeal-metastasis-from-breast-and-lung-cancers 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trial-compares-proton-therapy-to-standard-radiation-for-leptomeningeal-metastasis-from-breast-and-lung-cancers 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/flot-combination-takes-the-lead-in-localized-ge-cancer-targeted-oncology 2024-12-31T22:08:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/flot-combination-takes-the-lead-in-localized-ge-cancer-targeted-oncology 2024-12-31T22:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/omega-therapeutics-stock-hits-52-week-low-amid-financial-and-market-challenges 2024-12-31T20:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omega-therapeutics-stock-hits-52-week-low-amid-financial-and-market-challenges 2024-12-31T20:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/contagion-s-2024-top-stories-hepatitis-infections 2024-12-31T19:59:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/contagion-s-2024-top-stories-hepatitis-infections 2024-12-31T19:59:21+00:00 weekly 0.7 https://trial.medpath.com/news/merck-wins-uk-approval-for-lung-disease-drug-acquired-in-11-billion-deal-westlaw-today 2024-12-31T19:52:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-wins-uk-approval-for-lung-disease-drug-acquired-in-11-billion-deal-westlaw-today 2024-12-31T19:52:37+00:00 weekly 0.7 https://trial.medpath.com/news/veru-announces-the-sale-of-the-fc2-female-condom-r-internal-globenewswire 2024-12-31T19:32:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/veru-announces-the-sale-of-the-fc2-female-condom-r-internal-globenewswire 2024-12-31T19:32:06+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-s-2024-pillars-of-progress-top-news-in-hematology 2024-12-31T19:15:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-s-2024-pillars-of-progress-top-news-in-hematology 2024-12-31T19:15:31+00:00 weekly 0.7 https://trial.medpath.com/news/kazia-therapeutics-provides-update-on-paxalisib-regulatory-pathway-following-type-c 2024-12-31T19:09:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kazia-therapeutics-provides-update-on-paxalisib-regulatory-pathway-following-type-c 2024-12-31T19:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/explore-the-evolving-role-of-btk-inhibitors-in-cll-with-alexey-danilov-md-phd-onclive 2024-12-31T19:07:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/explore-the-evolving-role-of-btk-inhibitors-in-cll-with-alexey-danilov-md-phd-onclive 2024-12-31T19:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/immunocompromised-adults-show-weaker-response-to-rsv-vaccines-news-medical 2024-12-31T16:38:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunocompromised-adults-show-weaker-response-to-rsv-vaccines-news-medical 2024-12-31T16:38:11+00:00 weekly 0.7 https://trial.medpath.com/news/leqselvi-approval-tops-healio-s-most-read-alopecia-news-in-2024 2024-12-31T15:55:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leqselvi-approval-tops-healio-s-most-read-alopecia-news-in-2024 2024-12-31T15:55:10+00:00 weekly 0.7 https://trial.medpath.com/news/kazia-therapeutics-shares-fall-after-fda-declines-accelerated-drug-approval 2024-12-31T15:29:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kazia-therapeutics-shares-fall-after-fda-declines-accelerated-drug-approval 2024-12-31T15:29:30+00:00 weekly 0.7 https://trial.medpath.com/news/brii-bio-announces-signing-of-asset-purchase-agreements-acquiring-brii-179-ip-rights 2024-12-31T15:29:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brii-bio-announces-signing-of-asset-purchase-agreements-acquiring-brii-179-ip-rights 2024-12-31T15:29:13+00:00 weekly 0.7 https://trial.medpath.com/news/ec-approves-rybrevant-lazcluze-for-advanced-nsclc-treatment 2024-12-31T15:22:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ec-approves-rybrevant-lazcluze-for-advanced-nsclc-treatment 2024-12-31T15:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/miracle-new-drug-trial-shrinks-cruel-aggressive-bladder-cancer-uk-news-daily-express 2024-12-31T15:11:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/miracle-new-drug-trial-shrinks-cruel-aggressive-bladder-cancer-uk-news-daily-express 2024-12-31T15:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-therapeutics-submits-new-drug-application-for-relacorilant-to-treat-cushing-s-syndrome 2024-12-31T14:39:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corcept-therapeutics-submits-new-drug-application-for-relacorilant-to-treat-cushing-s-syndrome 2024-12-31T14:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-drug-appears-to-fight-lung-cancer-but-only-in-overweight-or-obese-patients 2024-12-31T14:06:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diabetes-drug-appears-to-fight-lung-cancer-but-only-in-overweight-or-obese-patients 2024-12-31T14:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/cocrystal-pharma-to-extend-phase-2a-influenza-challenge-study-with-oral-pb2-inhibitor-cc-42344 2024-12-31T13:20:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cocrystal-pharma-to-extend-phase-2a-influenza-challenge-study-with-oral-pb2-inhibitor-cc-42344 2024-12-31T13:20:38+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-precision-medicine-in-esophageal-squamous-cell-carcinoma-using-patient 2024-12-31T13:20:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancing-precision-medicine-in-esophageal-squamous-cell-carcinoma-using-patient 2024-12-31T13:20:07+00:00 weekly 0.7 https://trial.medpath.com/news/daily-hong-kong-stock-market-news-briefing-december-31-tuesday-longport 2024-12-31T13:14:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daily-hong-kong-stock-market-news-briefing-december-31-tuesday-longport 2024-12-31T13:14:51+00:00 weekly 0.7 https://trial.medpath.com/news/drug-repurposing-breakthroughs-established-medications-show-promise-in-cancer-lyme-disease-and-neurological-disorders 2024-12-31T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-repurposing-breakthroughs-established-medications-show-promise-in-cancer-lyme-disease-and-neurological-disorders 2024-12-31T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/managing-the-complex-balance-mpn-treatment-challenges-with-jak-inhibitors 2024-12-31T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/managing-the-complex-balance-mpn-treatment-challenges-with-jak-inhibitors 2024-12-31T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/safety-of-fezolinetant-for-treatment-of-moderate-to-severe-vasomotor-symptoms-due-to-menopause 2024-12-31T11:49:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-of-fezolinetant-for-treatment-of-moderate-to-severe-vasomotor-symptoms-due-to-menopause 2024-12-31T11:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/leerink-reiterates-outperform-rating-on-axsome-stock-amid-fda-uncertainty-for-auvelity 2024-12-31T10:09:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leerink-reiterates-outperform-rating-on-axsome-stock-amid-fda-uncertainty-for-auvelity 2024-12-31T10:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-part-d-expands-mtm-services-to-include-hiv-aids-coverage-in-2025 2024-12-31T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicare-part-d-expands-mtm-services-to-include-hiv-aids-coverage-in-2025 2024-12-31T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/medmira-reports-first-quarter-results-fy2025-biospace 2024-12-31T05:28:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medmira-reports-first-quarter-results-fy2025-biospace 2024-12-31T05:28:02+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-updates-2024-major-guideline-changes-across-multiple-cancer-types 2024-12-31T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nccn-updates-2024-major-guideline-changes-across-multiple-cancer-types 2024-12-31T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pioneer-in-lymphoma-research-dr-margaret-shipp-recognized-as-2024-giant-of-cancer-care 2024-12-31T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pioneer-in-lymphoma-research-dr-margaret-shipp-recognized-as-2024-giant-of-cancer-care 2024-12-31T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/preliminary-study-of-utilizing-a-patient-derived-tumor-spheroid-model-to-augment-precision-nature 2024-12-31T04:35:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/preliminary-study-of-utilizing-a-patient-derived-tumor-spheroid-model-to-augment-precision-nature 2024-12-31T04:35:36+00:00 weekly 0.7 https://trial.medpath.com/news/galera-therapeutics-completes-acquisition-of-nova-pharmaceuticals 2024-12-31T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/galera-therapeutics-completes-acquisition-of-nova-pharmaceuticals 2024-12-31T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pulmonology-in-2024-ai-integration-air-quality-crisis-and-advancing-lung-care-highlighted-in-annual-review 2024-12-31T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pulmonology-in-2024-ai-integration-air-quality-crisis-and-advancing-lung-care-highlighted-in-annual-review 2024-12-31T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cutia-therapeutics-completes-promising-phase-ii-trials-markets-insider 2024-12-31T02:35:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cutia-therapeutics-completes-promising-phase-ii-trials-markets-insider 2024-12-31T02:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/yuhan-s-lung-cancer-drug-leclaza-secures-european-approval-in-combination-therapy 2024-12-31T02:03:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yuhan-s-lung-cancer-drug-leclaza-secures-european-approval-in-combination-therapy 2024-12-31T02:03:43+00:00 weekly 0.7 https://trial.medpath.com/news/the-beam-dr-annemarie-shepherd-on-proton-therapy-for-thymic-cancers-napt-celebrates 2024-12-31T01:43:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-beam-dr-annemarie-shepherd-on-proton-therapy-for-thymic-cancers-napt-celebrates 2024-12-31T01:43:18+00:00 weekly 0.7 https://trial.medpath.com/news/continuous-glucose-monitoring-among-adults-with-type-2-diabetes-receiving-noninsulin-or-nature 2024-12-31T01:30:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/continuous-glucose-monitoring-among-adults-with-type-2-diabetes-receiving-noninsulin-or-nature 2024-12-31T01:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-single-and-double-catheter-intrathecal-drug-delivery-systems-in-nature 2024-12-31T00:16:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-single-and-double-catheter-intrathecal-drug-delivery-systems-in-nature 2024-12-31T00:16:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-authorization-of-drug-trump-touted-for-covid-19 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-revokes-authorization-of-drug-trump-touted-for-covid-19 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cerebral-palsy-global-clinical-trials-review-2024-clinical-trials-by-region-country-trial-status-trial-phase-sponsor-type-and-end-point-status 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cerebral-palsy-global-clinical-trials-review-2024-clinical-trials-by-region-country-trial-status-trial-phase-sponsor-type-and-end-point-status 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xbrane-resubmits-ranibizumab-biosimilar-bla-to-fda-following-complete-response-letter 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xbrane-resubmits-ranibizumab-biosimilar-bla-to-fda-following-complete-response-letter 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-findings-from-phase-2-keyvibe-002-trial-evaluating-an 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-announces-findings-from-phase-2-keyvibe-002-trial-evaluating-an 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/optima-trial-explores-predictive-test-for-chemotherapy-in-breast-cancer-treatment 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optima-trial-explores-predictive-test-for-chemotherapy-in-breast-cancer-treatment 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-sotagliflozin-for-type-1-diabetes-with-ckd-following-negative-advisory-review 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-rejects-sotagliflozin-for-type-1-diabetes-with-ckd-following-negative-advisory-review 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adc-therapeutics-announces-completion-of-enrollment-of-phase-3-confirmatory-clinical 2024-12-30T22:00:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adc-therapeutics-announces-completion-of-enrollment-of-phase-3-confirmatory-clinical 2024-12-30T22:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/agios-pharmaceuticals-advances-tebapivat-for-sickle-cell-disease-and-hemolytic-anemias 2024-12-30T21:59:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agios-pharmaceuticals-advances-tebapivat-for-sickle-cell-disease-and-hemolytic-anemias 2024-12-30T21:59:35+00:00 weekly 0.7 https://trial.medpath.com/news/nvp-healthcare-advances-oral-treatment-nvp-1805r2-for-cardiovascular-disorders 2024-12-30T21:59:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nvp-healthcare-advances-oral-treatment-nvp-1805r2-for-cardiovascular-disorders 2024-12-30T21:59:22+00:00 weekly 0.7 https://trial.medpath.com/news/taiho-pharmaceutical-advances-tas-0728-a-novel-her2-her3-inhibitor-for-multiple-solid-tumors 2024-12-30T21:57:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/taiho-pharmaceutical-advances-tas-0728-a-novel-her2-her3-inhibitor-for-multiple-solid-tumors 2024-12-30T21:57:43+00:00 weekly 0.7 https://trial.medpath.com/news/immedica-acquires-marinus-pharmaceuticals-for-151m-expanding-rare-disease-portfolio-with-ztalmy 2024-12-30T21:44:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immedica-acquires-marinus-pharmaceuticals-for-151m-expanding-rare-disease-portfolio-with-ztalmy 2024-12-30T21:44:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-to-verastem-s-breakthrough-ovarian-cancer-treatment-vstm 2024-12-30T21:37:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-verastem-s-breakthrough-ovarian-cancer-treatment-vstm 2024-12-30T21:37:53+00:00 weekly 0.7 https://trial.medpath.com/news/bria-imt-cancer-vaccine-shows-efficacy-tolerability-in-advanced-breast-cancer 2024-12-30T21:13:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bria-imt-cancer-vaccine-shows-efficacy-tolerability-in-advanced-breast-cancer 2024-12-30T21:13:23+00:00 weekly 0.7 https://trial.medpath.com/news/t-dxd-plus-pembrolizumab-elicits-responses-in-io-naive-her2-expressing-or-mutant-nsclc 2024-12-30T21:06:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t-dxd-plus-pembrolizumab-elicits-responses-in-io-naive-her2-expressing-or-mutant-nsclc 2024-12-30T21:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/novel-car-t-cell-therapy-trial-advances-to-third-cohort-in-ovarian-cancer 2024-12-30T20:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-car-t-cell-therapy-trial-advances-to-third-cohort-in-ovarian-cancer 2024-12-30T20:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kymera-s-stat3-degrader-kt-333-shows-promise-across-multiple-lymphomas-and-solid-tumors 2024-12-30T19:54:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kymera-s-stat3-degrader-kt-333-shows-promise-across-multiple-lymphomas-and-solid-tumors 2024-12-30T19:54:15+00:00 weekly 0.7 https://trial.medpath.com/news/incyte-s-alk2-inhibitor-zilurgisertib-fumarate-shows-promise-across-multiple-hematologic-disorders 2024-12-30T19:49:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incyte-s-alk2-inhibitor-zilurgisertib-fumarate-shows-promise-across-multiple-hematologic-disorders 2024-12-30T19:49:04+00:00 weekly 0.7 https://trial.medpath.com/news/november-s-phase-iii-successes-syros-cassava-tumble-on-misses-bioworld 2024-12-30T19:35:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/november-s-phase-iii-successes-syros-cassava-tumble-on-misses-bioworld 2024-12-30T19:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/d-boral-capital-served-as-exclusive-placement-agent-to-fibrobiologics-inc-nasdaq 2024-12-30T19:28:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/d-boral-capital-served-as-exclusive-placement-agent-to-fibrobiologics-inc-nasdaq 2024-12-30T19:28:22+00:00 weekly 0.7 https://trial.medpath.com/news/lumisystem-in-lumpectomy-may-reduce-or-omit-radiation-in-breast-cancer 2024-12-30T19:13:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lumisystem-in-lumpectomy-may-reduce-or-omit-radiation-in-breast-cancer 2024-12-30T19:13:32+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-pembrolizumab-to-chemo-improves-survival-in-cervical-cancer 2024-12-30T19:10:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-pembrolizumab-to-chemo-improves-survival-in-cervical-cancer 2024-12-30T19:10:56+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-s-oral-tyk2-inhibitor-zasocitinib-advances-development-for-multiple-autoimmune-conditions 2024-12-30T18:44:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/takeda-s-oral-tyk2-inhibitor-zasocitinib-advances-development-for-multiple-autoimmune-conditions 2024-12-30T18:44:38+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-s-orelabrutinib-shows-promise-in-treating-primary-immune-thrombocytopenia 2024-12-30T18:42:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innocare-s-orelabrutinib-shows-promise-in-treating-primary-immune-thrombocytopenia 2024-12-30T18:42:55+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-anti-pd1-immunotherapy-for-surgically-accessible-recurrent-glioblastoma-nature 2024-12-30T18:38:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-anti-pd1-immunotherapy-for-surgically-accessible-recurrent-glioblastoma-nature 2024-12-30T18:38:17+00:00 weekly 0.7 https://trial.medpath.com/news/kala-bio-announces-10750000-private-placement-biospace 2024-12-30T18:16:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kala-bio-announces-10750000-private-placement-biospace 2024-12-30T18:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/behavioral-intervention-decreases-how-much-pain-affects-daily-activities-in-people-with 2024-12-30T17:51:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/behavioral-intervention-decreases-how-much-pain-affects-daily-activities-in-people-with 2024-12-30T17:51:43+00:00 weekly 0.7 https://trial.medpath.com/news/psca-targeted-bpx-601-car-t-cells-with-pharmacological-activation-by-rimiducid-in 2024-12-30T17:38:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psca-targeted-bpx-601-car-t-cells-with-pharmacological-activation-by-rimiducid-in 2024-12-30T17:38:03+00:00 weekly 0.7 https://trial.medpath.com/news/trivalent-recombinant-protein-vaccine-induces-cross-neutralization-against-xbb-lineage-and 2024-12-30T17:20:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trivalent-recombinant-protein-vaccine-induces-cross-neutralization-against-xbb-lineage-and 2024-12-30T17:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/nos-inhibition-sensitizes-metaplastic-breast-cancer-to-pi3k-inhibition-and-taxane-therapy-via 2024-12-30T17:10:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nos-inhibition-sensitizes-metaplastic-breast-cancer-to-pi3k-inhibition-and-taxane-therapy-via 2024-12-30T17:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-says-new-drug-helps-children-with-rare-spinal-condition 2024-12-30T17:01:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-says-new-drug-helps-children-with-rare-spinal-condition 2024-12-30T17:01:42+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-therapeutics-presents-clinical-data-of-the-phagodair-pilot-study-with-results 2024-12-30T16:53:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phaxiam-therapeutics-presents-clinical-data-of-the-phagodair-pilot-study-with-results 2024-12-30T16:53:17+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-als-news-stories-of-2024 2024-12-30T16:23:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-als-news-stories-of-2024 2024-12-30T16:23:14+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-news-stories-of-2024-on-rare-disease-angioedema 2024-12-30T16:17:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-news-stories-of-2024-on-rare-disease-angioedema 2024-12-30T16:17:37+00:00 weekly 0.7 https://trial.medpath.com/news/relative-effectiveness-of-antidepressant-treatments-in-treatment-resistant-depression-nature 2024-12-30T14:41:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relative-effectiveness-of-antidepressant-treatments-in-treatment-resistant-depression-nature 2024-12-30T14:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-files-initial-section-of-u-s-new-drug 2024-12-30T14:19:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-files-initial-section-of-u-s-new-drug 2024-12-30T14:19:26+00:00 weekly 0.7 https://trial.medpath.com/news/radiopharm-announces-strategic-co-development-partnership-with-lantheus-for-australia 2024-12-30T13:12:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiopharm-announces-strategic-co-development-partnership-with-lantheus-for-australia 2024-12-30T13:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/determining-suitable-radioligand-therapy-use-in-neuroendocrine-tumors 2024-12-30T13:03:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/determining-suitable-radioligand-therapy-use-in-neuroendocrine-tumors 2024-12-30T13:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/handok-secures-approval-for-itp-treatment-doptelet-kbr 2024-12-30T13:02:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/handok-secures-approval-for-itp-treatment-doptelet-kbr 2024-12-30T13:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/accuracy-of-esat6-cfp10-skin-test-compared-with-tuberculin-skin-test-in-a-healthy-population 2024-12-30T12:40:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accuracy-of-esat6-cfp10-skin-test-compared-with-tuberculin-skin-test-in-a-healthy-population 2024-12-30T12:40:05+00:00 weekly 0.7 https://trial.medpath.com/news/axsome-s-alzheimer-s-drug-shows-promise-in-trials-by-investing-com 2024-12-30T12:27:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/axsome-s-alzheimer-s-drug-shows-promise-in-trials-by-investing-com 2024-12-30T12:27:16+00:00 weekly 0.7 https://trial.medpath.com/news/cspc-pharmaceutical-group-limited-s-leuprorelin-extended-release-injection-obtains 2024-12-30T12:23:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cspc-pharmaceutical-group-limited-s-leuprorelin-extended-release-injection-obtains 2024-12-30T12:23:25+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-to-precigen-s-prgn-2012-for-recurrent-respiratory-papillomatosis 2024-12-30T12:15:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-precigen-s-prgn-2012-for-recurrent-respiratory-papillomatosis 2024-12-30T12:15:19+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-advances-vicadrostat-development-for-chronic-kidney-disease-and-heart-failure 2024-12-30T11:38:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-ingelheim-advances-vicadrostat-development-for-chronic-kidney-disease-and-heart-failure 2024-12-30T11:38:24+00:00 weekly 0.7 https://trial.medpath.com/news/nevada-king-gold-reports-significant-discoveries-and-outlines-ambitious-2025-drill-program-at-atlanta-gold-project 2024-12-30T11:33:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nevada-king-gold-reports-significant-discoveries-and-outlines-ambitious-2025-drill-program-at-atlanta-gold-project 2024-12-30T11:33:32+00:00 weekly 0.7 https://trial.medpath.com/news/engaging-fathers-to-be-a-pilot-study-on-the-adaptation-and-programme-experience-of 2024-12-30T10:30:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/engaging-fathers-to-be-a-pilot-study-on-the-adaptation-and-programme-experience-of 2024-12-30T10:30:39+00:00 weekly 0.7 https://trial.medpath.com/news/leyden-labs-advances-novel-broad-spectrum-nasal-antibody-cr-9114-against-multiple-influenza-strains 2024-12-30T10:24:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leyden-labs-advances-novel-broad-spectrum-nasal-antibody-cr-9114-against-multiple-influenza-strains 2024-12-30T10:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/innovation-pharmaceuticals-brilacidin-shows-promise-across-multiple-therapeutic-areas 2024-12-30T10:19:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovation-pharmaceuticals-brilacidin-shows-promise-across-multiple-therapeutic-areas 2024-12-30T10:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/new-schizophrenia-drug-may-have-milder-side-effects-word-in-black 2024-12-30T10:14:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-schizophrenia-drug-may-have-milder-side-effects-word-in-black 2024-12-30T10:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-tecentriq-atezolizumab-expands-development-program-into-squamous-non-small-cell-lung-cancer 2024-12-30T10:08:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-tecentriq-atezolizumab-expands-development-program-into-squamous-non-small-cell-lung-cancer 2024-12-30T10:08:59+00:00 weekly 0.7 https://trial.medpath.com/news/the-efficacy-of-longer-term-lebrikizumab-treatment-in-patients-with-moderate-to-severe-pubmed 2024-12-30T09:48:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-efficacy-of-longer-term-lebrikizumab-treatment-in-patients-with-moderate-to-severe-pubmed 2024-12-30T09:48:54+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-s-e-visit-billing-program-shows-8-8-reduction-in-patient-portal-messages 2024-12-30T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-s-e-visit-billing-program-shows-8-8-reduction-in-patient-portal-messages 2024-12-30T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2024-marks-a-turning-point-in-weight-loss-for-floridians-with-anti-obesity-medications 2024-12-30T08:16:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-marks-a-turning-point-in-weight-loss-for-floridians-with-anti-obesity-medications 2024-12-30T08:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-rybrevant-r-amivantamab-in-globenewswire 2024-12-30T08:01:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-approves-rybrevant-r-amivantamab-in-globenewswire 2024-12-30T08:01:42+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-healthcare-news-in-2024-7-yuhan-s-leclaza-makes-us-entry-to-become-a-global 2024-12-30T07:42:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-healthcare-news-in-2024-7-yuhan-s-leclaza-makes-us-entry-to-become-a-global 2024-12-30T07:42:13+00:00 weekly 0.7 https://trial.medpath.com/news/participation-and-compliance-in-a-multimodal-prehabilitation-program-f-ppa 2024-12-30T07:29:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/participation-and-compliance-in-a-multimodal-prehabilitation-program-f-ppa 2024-12-30T07:29:42+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-significant-gap-between-pah-patient-and-physician-symptom-assessment 2024-12-30T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-significant-gap-between-pah-patient-and-physician-symptom-assessment 2024-12-30T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-s-dr-rafael-fonseca-pioneering-multiple-myeloma-research-and-treatment-revolution 2024-12-30T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-s-dr-rafael-fonseca-pioneering-multiple-myeloma-research-and-treatment-revolution 2024-12-30T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/critical-drug-shortages-persist-in-2024-despite-overall-decline-in-supply-disruptions 2024-12-30T05:57:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/critical-drug-shortages-persist-in-2024-despite-overall-decline-in-supply-disruptions 2024-12-30T05:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-intrathecal-onasemnogene-abeparvovec-phase-iii-globenewswire 2024-12-30T05:46:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-intrathecal-onasemnogene-abeparvovec-phase-iii-globenewswire 2024-12-30T05:46:02+00:00 weekly 0.7 https://trial.medpath.com/news/key-research-advances-in-mds-treatment-and-risk-assessment-2024-s-most-impactful-studies 2024-12-30T05:44:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-research-advances-in-mds-treatment-and-risk-assessment-2024-s-most-impactful-studies 2024-12-30T05:44:00+00:00 weekly 0.7 https://trial.medpath.com/news/zorifer-poised-to-fill-critical-gap-in-treatment-of-advanced-nsclc-with-cns-metastases-in 2024-12-30T05:34:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zorifer-poised-to-fill-critical-gap-in-treatment-of-advanced-nsclc-with-cns-metastases-in 2024-12-30T05:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/ruxolitinib-cream-shows-promise-in-pediatric-atopic-dermatitis-and-vitiligo-treatment-spd-2024-findings 2024-12-30T05:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ruxolitinib-cream-shows-promise-in-pediatric-atopic-dermatitis-and-vitiligo-treatment-spd-2024-findings 2024-12-30T05:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/340b-drug-program-faces-scrutiny-over-hospital-markups-and-transparency-issues-in-cancer-care 2024-12-30T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/340b-drug-program-faces-scrutiny-over-hospital-markups-and-transparency-issues-in-cancer-care 2024-12-30T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abion-s-c-met-targeted-anticancer-drug-phase-2-change-approved-by-fda-lazertinib 2024-12-30T04:47:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abion-s-c-met-targeted-anticancer-drug-phase-2-change-approved-by-fda-lazertinib 2024-12-30T04:47:24+00:00 weekly 0.7 https://trial.medpath.com/news/vincerx-pharma-enters-into-a-binding-term-sheet-for-a-strategic-merger-with-oqory-inc 2024-12-30T04:40:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vincerx-pharma-enters-into-a-binding-term-sheet-for-a-strategic-merger-with-oqory-inc 2024-12-30T04:40:10+00:00 weekly 0.7 https://trial.medpath.com/news/vor-bio-announces-55-6-million-private-placement-biospace 2024-12-30T04:40:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vor-bio-announces-55-6-million-private-placement-biospace 2024-12-30T04:40:05+00:00 weekly 0.7 https://trial.medpath.com/news/yoltech-therapeutics-granted-fda-orphan-drug-and-rare-pediatric-disease-designations 2024-12-30T04:39:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yoltech-therapeutics-granted-fda-orphan-drug-and-rare-pediatric-disease-designations 2024-12-30T04:39:58+00:00 weekly 0.7 https://trial.medpath.com/news/immune-biomarkers-show-promise-in-guiding-tnbc-treatment-decisions 2024-12-30T04:33:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immune-biomarkers-show-promise-in-guiding-tnbc-treatment-decisions 2024-12-30T04:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/carsgen-reports-positive-trial-results-for-cancer-therapy-markets-insider 2024-12-30T03:22:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/carsgen-reports-positive-trial-results-for-cancer-therapy-markets-insider 2024-12-30T03:22:49+00:00 weekly 0.7 https://trial.medpath.com/news/digital-biomarkers-revolutionize-respiratory-disease-management-new-hope-for-copd-and-asthma-patients 2024-12-30T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-biomarkers-revolutionize-respiratory-disease-management-new-hope-for-copd-and-asthma-patients 2024-12-30T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kintor-s-phase-iii-trial-milestone-for-hair-loss-treatment-tipranks-com 2024-12-30T00:12:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kintor-s-phase-iii-trial-milestone-for-hair-loss-treatment-tipranks-com 2024-12-30T00:12:32+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-s-2024-pillars-of-progress-top-news-in-ophthalmology 2024-12-30T00:00:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-s-2024-pillars-of-progress-top-news-in-ophthalmology 2024-12-30T00:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/exscientia-claims-world-first-as-ai-created-drug-enters-clinic 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exscientia-claims-world-first-as-ai-created-drug-enters-clinic 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/slrn-stock-touches-52-week-low-at-3-06-amid-market-challenges-by-investing-com 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/slrn-stock-touches-52-week-low-at-3-06-amid-market-challenges-by-investing-com 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/covid-19-pipeline-insights-clinical-trials-treatment-drugs-and-companies-2024-updated 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/covid-19-pipeline-insights-clinical-trials-treatment-drugs-and-companies-2024-updated 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-expands-car-t-therapy-kymriah-s-use-in-europe-outpacing-gilead-s-rival 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-expands-car-t-therapy-kymriah-s-use-in-europe-outpacing-gilead-s-rival 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthroughs-in-bladder-cancer-treatment-highlighted-in-2024 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthroughs-in-bladder-cancer-treatment-highlighted-in-2024 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/italian-multicenter-trial-evaluates-lifestyle-intervention-for-long-term-lymphoma-survivors 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/italian-multicenter-trial-evaluates-lifestyle-intervention-for-long-term-lymphoma-survivors 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-year-in-review-2024-top-stories-in-multiple-sclerosis 2024-12-29T23:09:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurologylive-r-year-in-review-2024-top-stories-in-multiple-sclerosis 2024-12-29T23:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-highlights-ai-s-role-in-stimulating-thought-caliber-az 2024-12-29T22:27:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-study-highlights-ai-s-role-in-stimulating-thought-caliber-az 2024-12-29T22:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/telix-files-tlx250-cdx-zircaix-r-bla-for-kidney-cancer-imaging-globenewswire 2024-12-29T21:59:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/telix-files-tlx250-cdx-zircaix-r-bla-for-kidney-cancer-imaging-globenewswire 2024-12-29T21:59:58+00:00 weekly 0.7 https://trial.medpath.com/news/cel-sci-secures-5-million-in-public-offering-to-advance-multikine-cancer-immunotherapy 2024-12-29T19:49:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cel-sci-secures-5-million-in-public-offering-to-advance-multikine-cancer-immunotherapy 2024-12-29T19:49:35+00:00 weekly 0.7 https://trial.medpath.com/news/jaaf-gtex-drive-sl-s-textile-innovation-and-competitiveness-daily-mirror 2024-12-29T19:21:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jaaf-gtex-drive-sl-s-textile-innovation-and-competitiveness-daily-mirror 2024-12-29T19:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/breakthroughs-and-battles-in-health-new-approvals-lawsuits-and-discoveries 2024-12-29T19:00:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthroughs-and-battles-in-health-new-approvals-lawsuits-and-discoveries 2024-12-29T19:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-kidney-cancer-stories-in-2024 2024-12-29T17:08:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-kidney-cancer-stories-in-2024 2024-12-29T17:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/2024-veterinary-news-in-review-3-dvm360 2024-12-29T16:08:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-veterinary-news-in-review-3-dvm360 2024-12-29T16:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/second-line-lenvatinib-shows-promising-pfs-in-advanced-hcc-oncology-nursing-news 2024-12-29T15:06:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/second-line-lenvatinib-shows-promising-pfs-in-advanced-hcc-oncology-nursing-news 2024-12-29T15:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/ivonescimab-chemo-combo-yields-positive-efficacy-and-safety-results-in-tnbc 2024-12-29T15:03:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ivonescimab-chemo-combo-yields-positive-efficacy-and-safety-results-in-tnbc 2024-12-29T15:03:08+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomized-trial-of-low-dose-thrombolysis-ultrasound-assisted-thrombolysis-or-heparin 2024-12-29T15:00:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-randomized-trial-of-low-dose-thrombolysis-ultrasound-assisted-thrombolysis-or-heparin 2024-12-29T15:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/have-the-new-pulmonary-hypertension-drugs-changed-the-game-medpage-today 2024-12-29T14:19:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/have-the-new-pulmonary-hypertension-drugs-changed-the-game-medpage-today 2024-12-29T14:19:34+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-year-in-review-2024-top-stories-in-movement-disorders 2024-12-29T13:55:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurologylive-r-year-in-review-2024-top-stories-in-movement-disorders 2024-12-29T13:55:31+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-secures-exclusive-license-for-novel-cancer-treatment-gurufocus 2024-12-29T12:38:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-biosciences-secures-exclusive-license-for-novel-cancer-treatment-gurufocus 2024-12-29T12:38:47+00:00 weekly 0.7 https://trial.medpath.com/news/io-biotech-faces-possible-nasdaq-delisting-over-low-stock-price 2024-12-29T12:24:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/io-biotech-faces-possible-nasdaq-delisting-over-low-stock-price 2024-12-29T12:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/aoh1996-targets-mitochondrial-dynamics-and-metabolism-in-leukemic-stem-cells-via 2024-12-29T10:52:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aoh1996-targets-mitochondrial-dynamics-and-metabolism-in-leukemic-stem-cells-via 2024-12-29T10:52:18+00:00 weekly 0.7 https://trial.medpath.com/news/short-interest-in-adlai-nortye-ltd-nasdaq-anl-increases-by-28-0-marketbeat 2024-12-29T10:44:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/short-interest-in-adlai-nortye-ltd-nasdaq-anl-increases-by-28-0-marketbeat 2024-12-29T10:44:04+00:00 weekly 0.7 https://trial.medpath.com/news/bio-path-holdings-advances-clinical-trials-and-secures-4-million-in-funding-citybuzz 2024-12-29T10:04:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bio-path-holdings-advances-clinical-trials-and-secures-4-million-in-funding-citybuzz 2024-12-29T10:04:25+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approvals-and-treatment-advances-mark-major-progress-in-pah-management-for-2024 2024-12-29T09:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approvals-and-treatment-advances-mark-major-progress-in-pah-management-for-2024 2024-12-29T09:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/early-detection-through-symptom-based-testing-shows-promise-in-ovarian-cancer-diagnosis 2024-12-29T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-detection-through-symptom-based-testing-shows-promise-in-ovarian-cancer-diagnosis 2024-12-29T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/leading-mds-expert-dr-garcia-manero-reflects-on-25-years-of-mentorship-and-innovation-at-md-anderson 2024-12-29T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leading-mds-expert-dr-garcia-manero-reflects-on-25-years-of-mentorship-and-innovation-at-md-anderson 2024-12-29T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/telehealth-proves-vital-for-rare-disease-management-post-pandemic-breaking-healthcare-access-barriers 2024-12-29T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/telehealth-proves-vital-for-rare-disease-management-post-pandemic-breaking-healthcare-access-barriers 2024-12-29T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/expert-insights-keys-to-successfully-transitioning-from-hematology-oncology-fellow-to-attending-physician 2024-12-29T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-insights-keys-to-successfully-transitioning-from-hematology-oncology-fellow-to-attending-physician 2024-12-29T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dermatology-times-2024-in-review-hidradenitis-suppurativa 2024-12-29T02:09:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dermatology-times-2024-in-review-hidradenitis-suppurativa 2024-12-29T02:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/biocardia-s-short-interest-declines-19-5-as-analysts-maintain-bullish-outlook 2024-12-28T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocardia-s-short-interest-declines-19-5-as-analysts-maintain-bullish-outlook 2024-12-28T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-nk-cell-therapy-myj-1633-shows-promise-for-multiple-cancer-types-including-her2-breast-cancer 2024-12-28T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-nk-cell-therapy-myj-1633-shows-promise-for-multiple-cancer-types-including-her2-breast-cancer 2024-12-28T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-prostate-cancer-articles-and-videos-of-2024-urology-times 2024-12-28T23:08:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-prostate-cancer-articles-and-videos-of-2024-urology-times 2024-12-28T23:08:57+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-year-in-review-2024-top-stories-in-headache-and-migraine 2024-12-28T22:09:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurologylive-r-year-in-review-2024-top-stories-in-headache-and-migraine 2024-12-28T22:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/new-pill-that-slows-down-alzheimer-s-being-considered-for-use-by-nhs-daily-express 2024-12-28T21:36:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-pill-that-slows-down-alzheimer-s-being-considered-for-use-by-nhs-daily-express 2024-12-28T21:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/2024-brings-change-new-hope-for-nonhormonal-management-of-menopause-hcplive 2024-12-28T19:37:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-brings-change-new-hope-for-nonhormonal-management-of-menopause-hcplive 2024-12-28T19:37:12+00:00 weekly 0.7 https://trial.medpath.com/news/contagion-s-2024-top-stories-c-difficile 2024-12-28T19:05:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/contagion-s-2024-top-stories-c-difficile 2024-12-28T19:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/iqvia-gets-cdsco-panel-nod-to-conduct-phase-iii-clinical-study-of-lumateperone 2024-12-28T17:47:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iqvia-gets-cdsco-panel-nod-to-conduct-phase-iii-clinical-study-of-lumateperone 2024-12-28T17:47:57+00:00 weekly 0.7 https://trial.medpath.com/news/zanidatamab-evorpacept-combo-yields-promising-activity-in-her2-breast-cancer 2024-12-28T17:08:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zanidatamab-evorpacept-combo-yields-promising-activity-in-her2-breast-cancer 2024-12-28T17:08:07+00:00 weekly 0.7 https://trial.medpath.com/news/china-developed-eye-cancer-drug-granted-fda-orphan-drug-designation 2024-12-28T16:38:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-developed-eye-cancer-drug-granted-fda-orphan-drug-designation 2024-12-28T16:38:23+00:00 weekly 0.7 https://trial.medpath.com/news/who-wants-a-pig-organ-patients-sick-and-tired-of-waiting-years-for-a-transplant-health 2024-12-28T16:16:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-wants-a-pig-organ-patients-sick-and-tired-of-waiting-years-for-a-transplant-health 2024-12-28T16:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/top-endovascular-news-of-2024-tctmd-com 2024-12-28T14:39:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-endovascular-news-of-2024-tctmd-com 2024-12-28T14:39:24+00:00 weekly 0.7 https://trial.medpath.com/news/cruise-ships-and-norovirus-don-t-mix-vax-before-travel 2024-12-28T14:30:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cruise-ships-and-norovirus-don-t-mix-vax-before-travel 2024-12-28T14:30:42+00:00 weekly 0.7 https://trial.medpath.com/news/faricimab-lacks-proof-of-added-benefit-over-comparator-therapies-for-macular-edema 2024-12-28T14:05:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/faricimab-lacks-proof-of-added-benefit-over-comparator-therapies-for-macular-edema 2024-12-28T14:05:07+00:00 weekly 0.7 https://trial.medpath.com/news/vaxart-secures-additional-4-6-m-for-covid-19-pill-vaccine-trial-investing-com-nigeria 2024-12-28T13:36:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaxart-secures-additional-4-6-m-for-covid-19-pill-vaccine-trial-investing-com-nigeria 2024-12-28T13:36:26+00:00 weekly 0.7 https://trial.medpath.com/news/probiotic-treatment-induces-changes-in-intestinal-microbiota-but-does-not-alter-scfa-levels 2024-12-28T13:12:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/probiotic-treatment-induces-changes-in-intestinal-microbiota-but-does-not-alter-scfa-levels 2024-12-28T13:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/fmba-has-begun-clinical-trials-of-a-vaccine-against-five-serotypes-of-meningococcus-news 2024-12-28T12:38:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fmba-has-begun-clinical-trials-of-a-vaccine-against-five-serotypes-of-meningococcus-news 2024-12-28T12:38:30+00:00 weekly 0.7 https://trial.medpath.com/news/earliest-clinical-trial-for-vco-to-end-in-december-next-year-for-avigan-doh-abs-cbn 2024-12-28T11:57:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earliest-clinical-trial-for-vco-to-end-in-december-next-year-for-avigan-doh-abs-cbn 2024-12-28T11:57:06+00:00 weekly 0.7 https://trial.medpath.com/news/evaluation-of-vascular-photobiomodulation-for-orofacial-pain-and-tension-type-headache 2024-12-28T11:50:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluation-of-vascular-photobiomodulation-for-orofacial-pain-and-tension-type-headache 2024-12-28T11:50:51+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-genitourinary-cancer-advances-in-2024-targeted-oncology 2024-12-28T10:06:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-genitourinary-cancer-advances-in-2024-targeted-oncology 2024-12-28T10:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-chronic-hand-eczema-treatment-tofacitinib-shows-promising-results 2024-12-28T09:17:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-chronic-hand-eczema-treatment-tofacitinib-shows-promising-results 2024-12-28T09:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-subcutaneous-nivolumab-in-advanced-or-metastatic-solid-tumors-onclive 2024-12-28T08:49:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-subcutaneous-nivolumab-in-advanced-or-metastatic-solid-tumors-onclive 2024-12-28T08:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/clinically-validated-classification-of-chronic-wounds-method-with-memristor-based-cellular 2024-12-28T08:26:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinically-validated-classification-of-chronic-wounds-method-with-memristor-based-cellular 2024-12-28T08:26:40+00:00 weekly 0.7 https://trial.medpath.com/news/headway-in-hepatology-resmetirom-s-historic-fda-approval-what-s-next-in-mash 2024-12-28T07:43:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/headway-in-hepatology-resmetirom-s-historic-fda-approval-what-s-next-in-mash 2024-12-28T07:43:35+00:00 weekly 0.7 https://trial.medpath.com/news/2024-rsv-vaccination-guidelines-strengthen-recommendations-for-adults-75-and-older 2024-12-28T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-rsv-vaccination-guidelines-strengthen-recommendations-for-adults-75-and-older 2024-12-28T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-carol-aghajanian-pioneering-patient-centric-innovation-in-gynecologic-cancer-treatment 2024-12-28T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-carol-aghajanian-pioneering-patient-centric-innovation-in-gynecologic-cancer-treatment 2024-12-28T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-tool-predicts-treatment-outcomes-for-brain-metastases-following-radiosurgery 2024-12-28T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-powered-tool-predicts-treatment-outcomes-for-brain-metastases-following-radiosurgery 2024-12-28T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/inside-the-battle-for-fda-approval-of-mdma-therapy-big-think 2024-12-28T03:31:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inside-the-battle-for-fda-approval-of-mdma-therapy-big-think 2024-12-28T03:31:22+00:00 weekly 0.7 https://trial.medpath.com/news/mezigdomide-combinations-show-promise-in-multiple-myeloma-medpage-today 2024-12-28T03:10:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mezigdomide-combinations-show-promise-in-multiple-myeloma-medpage-today 2024-12-28T03:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-articles-in-2024-for-oncology-apps-and-nurses 2024-12-28T03:04:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-articles-in-2024-for-oncology-apps-and-nurses 2024-12-28T03:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-gap-in-community-practice-training-for-hematology-oncology-fellows 2024-12-28T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-gap-in-community-practice-training-for-hematology-oncology-fellows 2024-12-28T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/greg-forlenza-md-discusses-clver-trial-among-newly-diagnosed-type-1-diabetes-patients 2024-12-28T02:37:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/greg-forlenza-md-discusses-clver-trial-among-newly-diagnosed-type-1-diabetes-patients 2024-12-28T02:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-roundup-december-27-2024-pr-newswire 2024-12-28T02:32:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-roundup-december-27-2024-pr-newswire 2024-12-28T02:32:53+00:00 weekly 0.7 https://trial.medpath.com/news/frontiers-comparative-efficacy-of-different-drugs-in-acute-heart-failure-with-renal-dysfunction 2024-12-28T02:02:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frontiers-comparative-efficacy-of-different-drugs-in-acute-heart-failure-with-renal-dysfunction 2024-12-28T02:02:37+00:00 weekly 0.7 https://trial.medpath.com/news/mixed-evidence-on-glp-1-medications-and-suicide-risk-a-2024-safety-analysis-review 2024-12-28T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mixed-evidence-on-glp-1-medications-and-suicide-risk-a-2024-safety-analysis-review 2024-12-28T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/optimizing-the-cumulative-cisplatin-dose-for-concurrent-chemoradiotherapy-beneficiaries 2024-12-28T01:54:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optimizing-the-cumulative-cisplatin-dose-for-concurrent-chemoradiotherapy-beneficiaries 2024-12-28T01:54:42+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomised-controlled-pilot-trial-protocol-for-patient-led-cognitive-gamified-training-during 2024-12-28T01:35:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-randomised-controlled-pilot-trial-protocol-for-patient-led-cognitive-gamified-training-during 2024-12-28T01:35:18+00:00 weekly 0.7 https://trial.medpath.com/news/eqbmed-broadens-reach-final-four-clinical-trial-sites-of-the-learning-phase-selected 2024-12-28T00:17:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eqbmed-broadens-reach-final-four-clinical-trial-sites-of-the-learning-phase-selected 2024-12-28T00:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-receives-fda-approval-for-cancer-treatment-marketwatch 2024-12-27T23:29:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-receives-fda-approval-for-cancer-treatment-marketwatch 2024-12-27T23:29:09+00:00 weekly 0.7 https://trial.medpath.com/news/citius-pharmaceuticals-inc-reports-fiscal-full-year-2024-financial-results-and-provides 2024-12-27T22:02:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/citius-pharmaceuticals-inc-reports-fiscal-full-year-2024-financial-results-and-provides 2024-12-27T22:02:15+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-subcutaneous-opdivo-extending-key-bms-franchise-into-2030s 2024-12-27T21:24:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-approves-subcutaneous-opdivo-extending-key-bms-franchise-into-2030s 2024-12-27T21:24:42+00:00 weekly 0.7 https://trial.medpath.com/news/nebraska-medicine-administers-novel-gene-therapy-to-first-hemophilia-patient 2024-12-27T21:09:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nebraska-medicine-administers-novel-gene-therapy-to-first-hemophilia-patient 2024-12-27T21:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/ebola-how-a-vaccine-turned-a-terrifying-virus-into-a-preventable-disease-cnn 2024-12-27T20:26:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ebola-how-a-vaccine-turned-a-terrifying-virus-into-a-preventable-disease-cnn 2024-12-27T20:26:17+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-pembrolizumab-plus-rt-may-enhance-dfs-outcomes-in-sarcomas 2024-12-27T19:07:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-pembrolizumab-plus-rt-may-enhance-dfs-outcomes-in-sarcomas 2024-12-27T19:07:52+00:00 weekly 0.7 https://trial.medpath.com/news/ema-s-chmp-recommends-approval-of-six-new-biosimilars-goodwin-jdsupra 2024-12-27T17:36:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-s-chmp-recommends-approval-of-six-new-biosimilars-goodwin-jdsupra 2024-12-27T17:36:04+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-most-viewed-liver-cancer-content-for-2024 2024-12-27T17:31:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-most-viewed-liver-cancer-content-for-2024 2024-12-27T17:31:40+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-stock-rises-24-in-3-months-here-s-why-yahoo-finance 2024-12-27T17:20:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-stock-rises-24-in-3-months-here-s-why-yahoo-finance 2024-12-27T17:20:29+00:00 weekly 0.7 https://trial.medpath.com/news/what-awaits-actinium-in-q4 2024-12-27T17:07:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-awaits-actinium-in-q4 2024-12-27T17:07:29+00:00 weekly 0.7 https://trial.medpath.com/news/sino-biopharmaceutical-limited-announces-positive-results-from-phase-iii-study-marketscreener 2024-12-27T16:30:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sino-biopharmaceutical-limited-announces-positive-results-from-phase-iii-study-marketscreener 2024-12-27T16:30:25+00:00 weekly 0.7 https://trial.medpath.com/news/avacta-group-advances-oncology-pipeline-with-novel-therapies-and-ai-collaboration 2024-12-27T16:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avacta-group-advances-oncology-pipeline-with-novel-therapies-and-ai-collaboration 2024-12-27T16:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/changes-in-gut-microbiota-after-gastric-cancer-surgery-a-prospective-longitudinal-study 2024-12-27T15:58:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/changes-in-gut-microbiota-after-gastric-cancer-surgery-a-prospective-longitudinal-study 2024-12-27T15:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/5-major-alzheimer-s-discoveries-scientists-made-in-2024-aol-com 2024-12-27T15:48:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-major-alzheimer-s-discoveries-scientists-made-in-2024-aol-com 2024-12-27T15:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/ucsd-researchers-clinically-validate-blood-pressure-monitoring-patch 2024-12-27T15:38:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucsd-researchers-clinically-validate-blood-pressure-monitoring-patch 2024-12-27T15:38:06+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-food-allergy-stories-of-2024-healio 2024-12-27T15:18:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-food-allergy-stories-of-2024-healio 2024-12-27T15:18:33+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-sees-insider-buying-from-leadership-team-and-board-members 2024-12-27T15:07:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiol-therapeutics-sees-insider-buying-from-leadership-team-and-board-members 2024-12-27T15:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/decentralized-clinical-trials-are-better-for-the-participants-and-for-the-planet-the-case-study 2024-12-27T14:55:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/decentralized-clinical-trials-are-better-for-the-participants-and-for-the-planet-the-case-study 2024-12-27T14:55:27+00:00 weekly 0.7 https://trial.medpath.com/news/cereno-scientific-has-enrolled-9-additional-patients-in-its-expanded-access-program-cision-news 2024-12-27T14:38:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cereno-scientific-has-enrolled-9-additional-patients-in-its-expanded-access-program-cision-news 2024-12-27T14:38:16+00:00 weekly 0.7 https://trial.medpath.com/news/cbd-may-reduce-alcohol-cravings-in-people-with-aud-study-finds-forbes 2024-12-27T14:01:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cbd-may-reduce-alcohol-cravings-in-people-with-aud-study-finds-forbes 2024-12-27T14:01:48+00:00 weekly 0.7 https://trial.medpath.com/news/painreform-provides-further-update-on-phase-3-clinical-trial-of-prf-110-globenewswire 2024-12-27T13:56:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/painreform-provides-further-update-on-phase-3-clinical-trial-of-prf-110-globenewswire 2024-12-27T13:56:29+00:00 weekly 0.7 https://trial.medpath.com/news/outlook-therapeutics-r-reports-financial-results-for-fiscal-year-2024-and-provides 2024-12-27T13:17:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/outlook-therapeutics-r-reports-financial-results-for-fiscal-year-2024-and-provides 2024-12-27T13:17:41+00:00 weekly 0.7 https://trial.medpath.com/news/top-mesothelioma-and-asbestos-news-in-2024 2024-12-27T12:58:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-mesothelioma-and-asbestos-news-in-2024 2024-12-27T12:58:09+00:00 weekly 0.7 https://trial.medpath.com/news/feasibility-study-and-pilot-rct-on-tourniquet-use-in-total-knee-replacement-surgery 2024-12-27T12:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/feasibility-study-and-pilot-rct-on-tourniquet-use-in-total-knee-replacement-surgery 2024-12-27T12:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/in-kids-with-crohn-s-disease-tnf-inhibitors-help-prevent-serious-complications-data-suggests 2024-12-27T12:12:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-kids-with-crohn-s-disease-tnf-inhibitors-help-prevent-serious-complications-data-suggests 2024-12-27T12:12:45+00:00 weekly 0.7 https://trial.medpath.com/news/chugai-obtains-regulatory-approval-for-lunsumio-for-intravenous-infusion-for-relapsed 2024-12-27T12:05:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chugai-obtains-regulatory-approval-for-lunsumio-for-intravenous-infusion-for-relapsed 2024-12-27T12:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/enrolment-patterns-in-a-randomized-controlled-trial-of-probiotics-in-critically-ill-patients 2024-12-27T11:29:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enrolment-patterns-in-a-randomized-controlled-trial-of-probiotics-in-critically-ill-patients 2024-12-27T11:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-tevimbra-chemotherapy-combination-for-first-line-treatment-of-advanced-esophageal-squamous-cell-carcinoma 2024-12-27T11:10:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-tevimbra-chemotherapy-combination-for-first-line-treatment-of-advanced-esophageal-squamous-cell-carcinoma 2024-12-27T11:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/argenx-announces-approval-of-vyvdura-efgartigimod-alfa-and-hyaluronidase-qvfc-in 2024-12-27T10:23:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/argenx-announces-approval-of-vyvdura-efgartigimod-alfa-and-hyaluronidase-qvfc-in 2024-12-27T10:23:34+00:00 weekly 0.7 https://trial.medpath.com/news/sensorion-announces-completion-of-enrollment-of-the-first-cohort-of-the-audiogene-biospace 2024-12-27T10:19:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sensorion-announces-completion-of-enrollment-of-the-first-cohort-of-the-audiogene-biospace 2024-12-27T10:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/relapsed-multiple-myeloma-clinical-trials-review-2024-globenewswire 2024-12-27T09:36:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relapsed-multiple-myeloma-clinical-trials-review-2024-globenewswire 2024-12-27T09:36:56+00:00 weekly 0.7 https://trial.medpath.com/news/dengue-fever-global-clinical-trials-review-2024-globenewswire 2024-12-27T09:35:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dengue-fever-global-clinical-trials-review-2024-globenewswire 2024-12-27T09:35:02+00:00 weekly 0.7 https://trial.medpath.com/news/updated-colonoscopy-guidelines-reshape-quality-metrics-as-family-physician-procedures-decline 2024-12-27T09:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/updated-colonoscopy-guidelines-reshape-quality-metrics-as-family-physician-procedures-decline 2024-12-27T09:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/ono-receives-supplemental-approval-of-opdivo-r-in-combination-with-cisplatin-and 2024-12-27T09:11:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ono-receives-supplemental-approval-of-opdivo-r-in-combination-with-cisplatin-and 2024-12-27T09:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/alto-neuroscience-presents-key-data-study-findings-on-alto-300-psychiatric-times 2024-12-27T08:00:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alto-neuroscience-presents-key-data-study-findings-on-alto-300-psychiatric-times 2024-12-27T08:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/novel-ruxolitinib-dosing-strategy-shows-promise-in-managing-anemic-myelofibrosis-patients 2024-12-27T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-ruxolitinib-dosing-strategy-shows-promise-in-managing-anemic-myelofibrosis-patients 2024-12-27T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pioneer-in-genitourinary-oncology-dr-christopher-logothetis-s-journey-from-greece-to-revolutionizing-cancer-care 2024-12-27T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pioneer-in-genitourinary-oncology-dr-christopher-logothetis-s-journey-from-greece-to-revolutionizing-cancer-care 2024-12-27T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-domestic-drug-for-one-type-of-cancer-has-been-registered-in-russia-oreanda-news 2024-12-27T07:29:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-domestic-drug-for-one-type-of-cancer-has-been-registered-in-russia-oreanda-news 2024-12-27T07:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/radiation-oncology-pioneer-ralph-weichselbaum-named-2024-giants-of-cancer-care-inductee 2024-12-27T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiation-oncology-pioneer-ralph-weichselbaum-named-2024-giants-of-cancer-care-inductee 2024-12-27T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ausperbio-secures-73-million-in-series-b-financing-to-advance-functional-cure-for-biospace 2024-12-27T05:00:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ausperbio-secures-73-million-in-series-b-financing-to-advance-functional-cure-for-biospace 2024-12-27T05:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-developments-in-waldenstrom-macroglobulinemia-treatment-btk-inhibitors-and-novel-therapies-show-promise 2024-12-27T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-developments-in-waldenstrom-macroglobulinemia-treatment-btk-inhibitors-and-novel-therapies-show-promise 2024-12-27T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/exicure-inc-partners-with-gpcr-therapeutics-to-fuel-new-growth-in-biotech-stock-titan 2024-12-27T03:18:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exicure-inc-partners-with-gpcr-therapeutics-to-fuel-new-growth-in-biotech-stock-titan 2024-12-27T03:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/sbrt-plus-sorafenib-boosts-os-over-sorafenib-alone-for-hcc-docwire-news 2024-12-27T01:14:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sbrt-plus-sorafenib-boosts-os-over-sorafenib-alone-for-hcc-docwire-news 2024-12-27T01:14:22+00:00 weekly 0.7 https://trial.medpath.com/news/enterprise-generative-ai-in-pharma-navigating-cautious-adoption-for-transformative-impact 2024-12-27T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enterprise-generative-ai-in-pharma-navigating-cautious-adoption-for-transformative-impact 2024-12-27T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-study-identifies-five-distinct-alzheimer-s-subtypes-paving-way-for-personalized-treatment 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-study-identifies-five-distinct-alzheimer-s-subtypes-paving-way-for-personalized-treatment 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adhd-medication-shows-promise-in-treating-methamphetamine-dependence 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adhd-medication-shows-promise-in-treating-methamphetamine-dependence 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innate-pharma-unveils-growth-strategy-and-highlights-clinical-trial-progress 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innate-pharma-unveils-growth-strategy-and-highlights-clinical-trial-progress 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rpt193-drug-hunter 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rpt193-drug-hunter 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tumor-mutational-burden-may-guide-treatment-in-metastatic-breast-cancer 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tumor-mutational-burden-may-guide-treatment-in-metastatic-breast-cancer 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immupharma-lon-imm-trading-down-7-3-here-s-why 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immupharma-lon-imm-trading-down-7-3-here-s-why 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advances-in-ophthalmology-2024-highlights 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-advances-in-ophthalmology-2024-highlights 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/recent-advances-in-medical-treatments-and-regulatory-approvals 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recent-advances-in-medical-treatments-and-regulatory-approvals 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-advances-in-nash-treatment-with-resmetirom-phase-3-trials 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/madrigal-pharmaceuticals-advances-in-nash-treatment-with-resmetirom-phase-3-trials 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/viracta-therapeutics-announces-closure-of-naval-1-clinical-globenewswire 2024-12-26T21:34:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viracta-therapeutics-announces-closure-of-naval-1-clinical-globenewswire 2024-12-26T21:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelic-alpha-s-top-11-stories-from-2024 2024-12-26T21:30:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psychedelic-alpha-s-top-11-stories-from-2024 2024-12-26T21:30:44+00:00 weekly 0.7 https://trial.medpath.com/news/cardiology-year-in-review-2024-hcplive 2024-12-26T21:04:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiology-year-in-review-2024-hcplive 2024-12-26T21:04:23+00:00 weekly 0.7 https://trial.medpath.com/news/tislelizumab-triplet-shows-meaningful-responses-pfs-in-metastatic-tnbc 2024-12-26T21:02:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tislelizumab-triplet-shows-meaningful-responses-pfs-in-metastatic-tnbc 2024-12-26T21:02:46+00:00 weekly 0.7 https://trial.medpath.com/news/sermonix-and-henlius-dose-first-chinese-patient-in-phase-3-globenewswire 2024-12-26T20:42:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sermonix-and-henlius-dose-first-chinese-patient-in-phase-3-globenewswire 2024-12-26T20:42:06+00:00 weekly 0.7 https://trial.medpath.com/news/ohtuvayre-from-verona-pharma-pharmacy-times 2024-12-26T20:06:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ohtuvayre-from-verona-pharma-pharmacy-times 2024-12-26T20:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-may-increase-aes-in-hr-her2-breast-cancer-treatment 2024-12-26T19:08:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirzepatide-may-increase-aes-in-hr-her2-breast-cancer-treatment 2024-12-26T19:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/cardiology-most-read-stories-from-2024-drug-topics 2024-12-26T17:51:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiology-most-read-stories-from-2024-drug-topics 2024-12-26T17:51:20+00:00 weekly 0.7 https://trial.medpath.com/news/preliminary-evidence-of-renal-function-improvement-newswise 2024-12-26T17:23:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/preliminary-evidence-of-renal-function-improvement-newswise 2024-12-26T17:23:08+00:00 weekly 0.7 https://trial.medpath.com/news/the-affects-of-env-101-on-ipf-pharmaceutical-executive 2024-12-26T17:15:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-affects-of-env-101-on-ipf-pharmaceutical-executive 2024-12-26T17:15:47+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-pharmaceuticals-stock-is-down-13-here-s-why-you-should-buy-the-dip 2024-12-26T16:55:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-stock-is-down-13-here-s-why-you-should-buy-the-dip 2024-12-26T16:55:11+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-roundup-nvo-s-obesity-study-failure-fda-nod-to-pfe-lly-barchart-com 2024-12-26T16:25:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-stock-roundup-nvo-s-obesity-study-failure-fda-nod-to-pfe-lly-barchart-com 2024-12-26T16:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-stories-from-the-2024-san-antonio-breast-cancer-symposium-cure-today 2024-12-26T16:06:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-stories-from-the-2024-san-antonio-breast-cancer-symposium-cure-today 2024-12-26T16:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/immunogenicity-reactogenicity-and-safety-of-a-pentavalent-meningococcal-abcwy-pubmed 2024-12-26T15:58:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunogenicity-reactogenicity-and-safety-of-a-pentavalent-meningococcal-abcwy-pubmed 2024-12-26T15:58:26+00:00 weekly 0.7 https://trial.medpath.com/news/os-therapies-partners-with-b2i-digital-to-engage-with-biotech-investors-online-stock-titan 2024-12-26T15:23:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/os-therapies-partners-with-b2i-digital-to-engage-with-biotech-investors-online-stock-titan 2024-12-26T15:23:47+00:00 weekly 0.7 https://trial.medpath.com/news/rx-road-map-erdafitinib-balversa-oncology-nursing-news 2024-12-26T15:02:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rx-road-map-erdafitinib-balversa-oncology-nursing-news 2024-12-26T15:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-individualized-versus-conventional-perioperative-blood-pressure-management-on-trials 2024-12-26T14:33:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effect-of-individualized-versus-conventional-perioperative-blood-pressure-management-on-trials 2024-12-26T14:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/casi-pharmaceuticals-faces-clinical-hold-on-cid-103-by-fda-tipranks-com 2024-12-26T14:00:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/casi-pharmaceuticals-faces-clinical-hold-on-cid-103-by-fda-tipranks-com 2024-12-26T14:00:09+00:00 weekly 0.7 https://trial.medpath.com/news/assembly-biosciences-reports-interim-phase-1b-results-from-clinical-trial-evaluating-next 2024-12-26T13:16:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/assembly-biosciences-reports-interim-phase-1b-results-from-clinical-trial-evaluating-next 2024-12-26T13:16:32+00:00 weekly 0.7 https://trial.medpath.com/news/the-chase-for-novel-oral-glp-1-obesity-meds-adds-a-new-contender-medcity-news 2024-12-26T13:11:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-chase-for-novel-oral-glp-1-obesity-meds-adds-a-new-contender-medcity-news 2024-12-26T13:11:37+00:00 weekly 0.7 https://trial.medpath.com/news/managing-young-mpn-patients-balancing-long-term-treatment-risks-and-benefits 2024-12-26T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/managing-young-mpn-patients-balancing-long-term-treatment-risks-and-benefits 2024-12-26T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/palvella-therapeutics-stock-gains-attention-with-phase-3-trial-data-expected-in-early-2026 2024-12-26T12:23:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palvella-therapeutics-stock-gains-attention-with-phase-3-trial-data-expected-in-early-2026 2024-12-26T12:23:31+00:00 weekly 0.7 https://trial.medpath.com/news/polypid-stock-poised-for-2026-launch-despite-adjusted-target-from-hc-wainwright 2024-12-26T12:23:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/polypid-stock-poised-for-2026-launch-despite-adjusted-target-from-hc-wainwright 2024-12-26T12:23:30+00:00 weekly 0.7 https://trial.medpath.com/news/genomic-scarring-score-predicts-the-response-to-parp-inhibitors-in-non-small-cell-lung-cancer 2024-12-26T12:22:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genomic-scarring-score-predicts-the-response-to-parp-inhibitors-in-non-small-cell-lung-cancer 2024-12-26T12:22:14+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-year-in-review-2024-top-conference-coverage-stories 2024-12-26T11:33:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurologylive-r-year-in-review-2024-top-conference-coverage-stories 2024-12-26T11:33:13+00:00 weekly 0.7 https://trial.medpath.com/news/microtech-announces-first-human-case-of-implantable-microsensor-for-heart-failure 2024-12-26T11:20:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/microtech-announces-first-human-case-of-implantable-microsensor-for-heart-failure 2024-12-26T11:20:11+00:00 weekly 0.7 https://trial.medpath.com/news/ind-application-for-a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous 2024-12-26T09:49:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ind-application-for-a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous 2024-12-26T09:49:33+00:00 weekly 0.7 https://trial.medpath.com/news/dravet-syndrome-severe-myoclonic-epilepsy-of-infancy-global-clinical-trials-review-2024 2024-12-26T09:37:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dravet-syndrome-severe-myoclonic-epilepsy-of-infancy-global-clinical-trials-review-2024 2024-12-26T09:37:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-mandates-standardized-asbestos-testing-protocol-for-talc-based-cosmetics 2024-12-26T09:33:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-mandates-standardized-asbestos-testing-protocol-for-talc-based-cosmetics 2024-12-26T09:33:31+00:00 weekly 0.7 https://trial.medpath.com/news/tiumbio-s-hemophilia-novel-drug-candidate-tu7710-achieves-successful-results-in-phase 2024-12-26T07:11:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tiumbio-s-hemophilia-novel-drug-candidate-tu7710-achieves-successful-results-in-phase 2024-12-26T07:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/novel-research-reveals-uchl1-as-therapeutic-target-in-ovarian-cancer-and-western-diet-s-impact-on-liver-cancer 2024-12-26T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-research-reveals-uchl1-as-therapeutic-target-in-ovarian-cancer-and-western-diet-s-impact-on-liver-cancer 2024-12-26T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-data-validates-venetoclax-s-efficacy-in-cll-patients-after-btk-inhibitor-treatment 2024-12-26T06:17:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-data-validates-venetoclax-s-efficacy-in-cll-patients-after-btk-inhibitor-treatment 2024-12-26T06:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/georgetown-oncologist-dr-john-marshall-s-journey-from-personal-loss-to-pioneering-gi-cancer-care 2024-12-26T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/georgetown-oncologist-dr-john-marshall-s-journey-from-personal-loss-to-pioneering-gi-cancer-care 2024-12-26T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/key-copd-research-highlights-mortality-risks-treatment-effects-and-biomarkers-in-2024 2024-12-26T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-copd-research-highlights-mortality-risks-treatment-effects-and-biomarkers-in-2024 2024-12-26T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacy-prescribing-trials-provide-access-to-immediate-care-hmri 2024-12-26T05:28:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmacy-prescribing-trials-provide-access-to-immediate-care-hmri 2024-12-26T05:28:25+00:00 weekly 0.7 https://trial.medpath.com/news/lirodegimod-drug-targets-indications-patents 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lirodegimod-drug-targets-indications-patents 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/systemic-sclerosis-clinical-trials-2024-ema-pdma-fda 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/systemic-sclerosis-clinical-trials-2024-ema-pdma-fda 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/telisotuzumab-vedotin-shows-promise-in-treating-c-met-positive-non-small-cell-lung-cancer 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/telisotuzumab-vedotin-shows-promise-in-treating-c-met-positive-non-small-cell-lung-cancer 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rxrx-stock-surges-with-promising-trials-whats-next-for-investors 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rxrx-stock-surges-with-promising-trials-whats-next-for-investors 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-emotional-therapy-shows-superior-pain-reduction-in-veterans-compared-to-cbt 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-emotional-therapy-shows-superior-pain-reduction-in-veterans-compared-to-cbt 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/automated-insulin-delivery-systems-enhance-glycaemic-control-in-youth-with-type-1-diabetes 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/automated-insulin-delivery-systems-enhance-glycaemic-control-in-youth-with-type-1-diabetes 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-keytruda-faces-new-competition-in-cancer-treatment-arena 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-keytruda-faces-new-competition-in-cancer-treatment-arena 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/xanomeline-trospium-chloride-first-approval-springermedicine-com 2024-12-25T23:45:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xanomeline-trospium-chloride-first-approval-springermedicine-com 2024-12-25T23:45:02+00:00 weekly 0.7 https://trial.medpath.com/news/gecacitinib-demonstrates-safety-efficacy-over-hydroxyurea-in-patients-with-myelofibrosis 2024-12-25T23:06:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gecacitinib-demonstrates-safety-efficacy-over-hydroxyurea-in-patients-with-myelofibrosis 2024-12-25T23:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-cancer-vaccine-stories-from-2024-cure-today 2024-12-25T19:14:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-cancer-vaccine-stories-from-2024-cure-today 2024-12-25T19:14:13+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-for-alzheimer-s-what-drives-brain-age-primary-care-alzheimer-s-guideline 2024-12-25T18:02:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-for-alzheimer-s-what-drives-brain-age-primary-care-alzheimer-s-guideline 2024-12-25T18:02:11+00:00 weekly 0.7 https://trial.medpath.com/news/biosimilar-market-achieves-major-breakthrough-in-2024-with-61-fda-approvals-and-12-4b-in-healthcare-savings 2024-12-25T17:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biosimilar-market-achieves-major-breakthrough-in-2024-with-61-fda-approvals-and-12-4b-in-healthcare-savings 2024-12-25T17:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/preliminary-results-of-qilu-pharmaceutical-s-phase-ia-study-on-gprc5d-cd3-targeting 2024-12-25T16:57:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/preliminary-results-of-qilu-pharmaceutical-s-phase-ia-study-on-gprc5d-cd3-targeting 2024-12-25T16:57:22+00:00 weekly 0.7 https://trial.medpath.com/news/transcranial-magnetic-stimulation-for-teenage-depression-psychology-today 2024-12-25T15:49:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transcranial-magnetic-stimulation-for-teenage-depression-psychology-today 2024-12-25T15:49:59+00:00 weekly 0.7 https://trial.medpath.com/news/ropeginterferon-alfa-2b-response-improves-with-nfkb1-haplotype-in-pv-and-et 2024-12-25T15:10:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ropeginterferon-alfa-2b-response-improves-with-nfkb1-haplotype-in-pv-and-et 2024-12-25T15:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/optimizing-infusion-chair-time-for-oncology-trials-follow-up-study 2024-12-25T14:06:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optimizing-infusion-chair-time-for-oncology-trials-follow-up-study 2024-12-25T14:06:20+00:00 weekly 0.7 https://trial.medpath.com/news/stem-cell-therapy-offers-new-hope-for-children-with-heart-failure 2024-12-25T13:54:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stem-cell-therapy-offers-new-hope-for-children-with-heart-failure 2024-12-25T13:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-therapies-and-combinations-augment-melanoma-treatment-arsenal-onclive 2024-12-25T13:07:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-therapies-and-combinations-augment-melanoma-treatment-arsenal-onclive 2024-12-25T13:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/precision-trial-hcplive 2024-12-25T13:03:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-trial-hcplive 2024-12-25T13:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/transformative-or-transitional-deciphering-the-role-of-niagara-in-shaping-future-practice 2024-12-25T12:59:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transformative-or-transitional-deciphering-the-role-of-niagara-in-shaping-future-practice 2024-12-25T12:59:35+00:00 weekly 0.7 https://trial.medpath.com/news/medmira-receives-health-canada-approval-for-its-multiplo-r-rapid-tp-hiv-test-for 2024-12-25T12:38:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medmira-receives-health-canada-approval-for-its-multiplo-r-rapid-tp-hiv-test-for 2024-12-25T12:38:42+00:00 weekly 0.7 https://trial.medpath.com/news/imcivree-label-expanded-weight-loss-with-weekly-injection-kidney-donation-chain 2024-12-25T11:32:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imcivree-label-expanded-weight-loss-with-weekly-injection-kidney-donation-chain 2024-12-25T11:32:20+00:00 weekly 0.7 https://trial.medpath.com/news/dreamm-11-part-2-japanese-phase-i-trial-of-belantamab-mafodotin-combination-therapies 2024-12-25T09:50:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dreamm-11-part-2-japanese-phase-i-trial-of-belantamab-mafodotin-combination-therapies 2024-12-25T09:50:18+00:00 weekly 0.7 https://trial.medpath.com/news/mass-balance-recovery-absorption-metabolism-and-excretion-of-elinzanetant-in-healthy 2024-12-25T09:50:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mass-balance-recovery-absorption-metabolism-and-excretion-of-elinzanetant-in-healthy 2024-12-25T09:50:01+00:00 weekly 0.7 https://trial.medpath.com/news/samsung-bioepis-advances-denosumab-biosimilar-sb16-for-osteoporosis-and-oncology-indications 2024-12-25T09:11:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/samsung-bioepis-advances-denosumab-biosimilar-sb16-for-osteoporosis-and-oncology-indications 2024-12-25T09:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/mindmed-stock-skyrockets-94-year-to-date-what-s-driving-it-yahoo-finance 2024-12-25T08:47:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mindmed-stock-skyrockets-94-year-to-date-what-s-driving-it-yahoo-finance 2024-12-25T08:47:35+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-shares-retain-buy-rating-as-pivotal-phase-3-aspire-study-begins-for-angelman-syndrome 2024-12-25T06:31:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultragenyx-shares-retain-buy-rating-as-pivotal-phase-3-aspire-study-begins-for-angelman-syndrome 2024-12-25T06:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/novel-integrated-palliative-care-training-program-shows-promise-for-hematology-oncology-fellows 2024-12-25T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-integrated-palliative-care-training-program-shows-promise-for-hematology-oncology-fellows 2024-12-25T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/statin-therapy-shows-significant-cardiovascular-risk-reduction-in-elderly-patients-over-75 2024-12-25T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/statin-therapy-shows-significant-cardiovascular-risk-reduction-in-elderly-patients-over-75 2024-12-25T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/brain-foundation-issues-rfp-research-to-benefit-individuals-with-autism-rfps-pnd 2024-12-25T05:21:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brain-foundation-issues-rfp-research-to-benefit-individuals-with-autism-rfps-pnd 2024-12-25T05:21:24+00:00 weekly 0.7 https://trial.medpath.com/news/top-healthcare-experts-share-insights-on-obesity-management-primary-care-innovation-and-health-equity-in-2024-ivbm-coverage 2024-12-25T03:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-healthcare-experts-share-insights-on-obesity-management-primary-care-innovation-and-health-equity-in-2024-ivbm-coverage 2024-12-25T03:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/castle-biosciences-reports-preliminary-data-from-atopic-dermatitis-test-study 2024-12-25T02:34:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/castle-biosciences-reports-preliminary-data-from-atopic-dermatitis-test-study 2024-12-25T02:34:41+00:00 weekly 0.7 https://trial.medpath.com/news/basilea-receives-additional-funding-from-carb-x-to-advance-antibiotic-candidate 2024-12-25T00:35:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/basilea-receives-additional-funding-from-carb-x-to-advance-antibiotic-candidate 2024-12-25T00:35:24+00:00 weekly 0.7 https://trial.medpath.com/news/ustekinumab-biosimilar-by-celltrion-for-psoriatic-arthritis-likelihood 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ustekinumab-biosimilar-by-celltrion-for-psoriatic-arthritis-likelihood 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-partners-with-walgreens-for-obesity-and-diabetes-clinical-trial 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-ingelheim-partners-with-walgreens-for-obesity-and-diabetes-clinical-trial 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cd20-bispecific-antibodies-show-promise-in-lymphoma-treatment-at-ash 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cd20-bispecific-antibodies-show-promise-in-lymphoma-treatment-at-ash 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-says-decongestant-in-many-cold-medicines-doesn-t-work-so-what-does-fox-13-memphis 2024-12-24T22:57:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-says-decongestant-in-many-cold-medicines-doesn-t-work-so-what-does-fox-13-memphis 2024-12-24T22:57:28+00:00 weekly 0.7 https://trial.medpath.com/news/guess-which-asx-healthcare-stock-is-jumping-7-on-us-fda-approval-news-motley-fool 2024-12-24T22:38:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/guess-which-asx-healthcare-stock-is-jumping-7-on-us-fda-approval-news-motley-fool 2024-12-24T22:38:35+00:00 weekly 0.7 https://trial.medpath.com/news/new-smartphone-app-successfully-treats-tinnitus-in-clinical-trial-the-brighter-side-of-news 2024-12-24T21:15:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-smartphone-app-successfully-treats-tinnitus-in-clinical-trial-the-brighter-side-of-news 2024-12-24T21:15:12+00:00 weekly 0.7 https://trial.medpath.com/news/autologous-tumor-lysate-loaded-dendritic-cell-vaccination-in-glioblastoma-patients 2024-12-24T21:09:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autologous-tumor-lysate-loaded-dendritic-cell-vaccination-in-glioblastoma-patients 2024-12-24T21:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/new-ptsd-treatment-shows-promise-with-brexpiprazole-sertraline-combination 2024-12-24T19:55:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-ptsd-treatment-shows-promise-with-brexpiprazole-sertraline-combination 2024-12-24T19:55:01+00:00 weekly 0.7 https://trial.medpath.com/news/mariposa-trial-shows-pfs-benefit-with-or-without-cns-disease-in-nsclc 2024-12-24T19:31:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mariposa-trial-shows-pfs-benefit-with-or-without-cns-disease-in-nsclc 2024-12-24T19:31:14+00:00 weekly 0.7 https://trial.medpath.com/news/prophylactic-approaches-lessen-immune-related-reactions-in-nsclc-cancer-network 2024-12-24T19:02:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prophylactic-approaches-lessen-immune-related-reactions-in-nsclc-cancer-network 2024-12-24T19:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-flurry-of-drugs-ahead-of-holiday-season-pharmaphorum 2024-12-24T18:50:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-flurry-of-drugs-ahead-of-holiday-season-pharmaphorum 2024-12-24T18:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/research-supports-need-for-diversity-in-hemophilia-trials-and-reducing-resource-strain 2024-12-24T18:42:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-supports-need-for-diversity-in-hemophilia-trials-and-reducing-resource-strain 2024-12-24T18:42:19+00:00 weekly 0.7 https://trial.medpath.com/news/journey-medical-corporation-announces-fda-approval-of-emrositm-for-rosacea-treatment 2024-12-24T18:25:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/journey-medical-corporation-announces-fda-approval-of-emrositm-for-rosacea-treatment 2024-12-24T18:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/where-do-psychedelics-fit-in-the-future-of-psychiatry-psychiatric-times 2024-12-24T18:06:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/where-do-psychedelics-fit-in-the-future-of-psychiatry-psychiatric-times 2024-12-24T18:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/clearmind-medicine-receives-irb-approval-for-its-fda-regulated-clinical-trial-stock-titan 2024-12-24T17:58:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clearmind-medicine-receives-irb-approval-for-its-fda-regulated-clinical-trial-stock-titan 2024-12-24T17:58:57+00:00 weekly 0.7 https://trial.medpath.com/news/innovation-collaboration-and-performance-were-highlights-for-ema-in-2024-pharmtech 2024-12-24T17:39:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovation-collaboration-and-performance-were-highlights-for-ema-in-2024-pharmtech 2024-12-24T17:39:51+00:00 weekly 0.7 https://trial.medpath.com/news/progress-of-immune-checkpoint-inhibitors-therapy-for-pmmr-mss-metastat-ott 2024-12-24T17:34:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/progress-of-immune-checkpoint-inhibitors-therapy-for-pmmr-mss-metastat-ott 2024-12-24T17:34:41+00:00 weekly 0.7 https://trial.medpath.com/news/biocon-zentiva-get-eu-approval-for-generic-diabetes-weight-management-drug-the-hindu 2024-12-24T17:27:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocon-zentiva-get-eu-approval-for-generic-diabetes-weight-management-drug-the-hindu 2024-12-24T17:27:14+00:00 weekly 0.7 https://trial.medpath.com/news/hospitals-trial-ai-to-spot-type-2-diabetes-risk-bbc 2024-12-24T15:17:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hospitals-trial-ai-to-spot-type-2-diabetes-risk-bbc 2024-12-24T15:17:11+00:00 weekly 0.7 https://trial.medpath.com/news/ractigen-therapeutics-announces-first-patient-dosed-in-phase-i-clinical-trial-for-rag-17-in 2024-12-24T15:07:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ractigen-therapeutics-announces-first-patient-dosed-in-phase-i-clinical-trial-for-rag-17-in 2024-12-24T15:07:50+00:00 weekly 0.7 https://trial.medpath.com/news/os-therapies-announces-pricing-of-6-million-private-placement-stock-titan 2024-12-24T14:45:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/os-therapies-announces-pricing-of-6-million-private-placement-stock-titan 2024-12-24T14:45:35+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-launched-phase-3-trial-for-ibuzatrelvir-new-oral-antiviral-for-covid-19-treatment 2024-12-24T14:11:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-launched-phase-3-trial-for-ibuzatrelvir-new-oral-antiviral-for-covid-19-treatment 2024-12-24T14:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-developments-in-car-t-treatments-webinar-series-summary-cancer-network 2024-12-24T14:02:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-developments-in-car-t-treatments-webinar-series-summary-cancer-network 2024-12-24T14:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/enanta-pharmaceuticals-stock-remains-buy-rated-with-phase-2-data-driving-model-revisions 2024-12-24T14:01:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enanta-pharmaceuticals-stock-remains-buy-rated-with-phase-2-data-driving-model-revisions 2024-12-24T14:01:56+00:00 weekly 0.7 https://trial.medpath.com/news/novel-radiogenomics-approach-to-predict-and-characterize-pneumonitis-in-stage-iii-nsclc 2024-12-24T13:51:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-radiogenomics-approach-to-predict-and-characterize-pneumonitis-in-stage-iii-nsclc 2024-12-24T13:51:48+00:00 weekly 0.7 https://trial.medpath.com/news/precision-pathways-targeted-therapies-mutation-driven-treatment-strategies 2024-12-24T13:12:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-pathways-targeted-therapies-mutation-driven-treatment-strategies 2024-12-24T13:12:11+00:00 weekly 0.7 https://trial.medpath.com/news/2-year-results-from-an-observational-study-of-proactive-treatment-regimens-with-intravitreal-nature 2024-12-24T12:38:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2-year-results-from-an-observational-study-of-proactive-treatment-regimens-with-intravitreal-nature 2024-12-24T12:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/biocon-shares-ascend-5-as-company-receives-approval-for-diabetes-drug-in-eu-upstox 2024-12-24T11:37:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocon-shares-ascend-5-as-company-receives-approval-for-diabetes-drug-in-eu-upstox 2024-12-24T11:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-reveals-shingles-infection-significantly-increases-risk-of-parkinson-s-and-dementia 2024-12-24T11:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meta-analysis-reveals-shingles-infection-significantly-increases-risk-of-parkinson-s-and-dementia 2024-12-24T11:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/hanmi-pharm-seeks-approval-for-triple-combination-hypertension-drug-pharma-article-kbr 2024-12-24T11:29:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hanmi-pharm-seeks-approval-for-triple-combination-hypertension-drug-pharma-article-kbr 2024-12-24T11:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/pyelonephritis-global-clinical-trials-review-2024-yahoo-finance 2024-12-24T09:19:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pyelonephritis-global-clinical-trials-review-2024-yahoo-finance 2024-12-24T09:19:50+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-high-frequency-of-ivig-related-adverse-events-in-pediatric-patients 2024-12-24T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-high-frequency-of-ivig-related-adverse-events-in-pediatric-patients 2024-12-24T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-boosts-vaccine-development-amid-egg-recall-crisis-the-pinnacle-gazette 2024-12-24T08:55:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-boosts-vaccine-development-amid-egg-recall-crisis-the-pinnacle-gazette 2024-12-24T08:55:37+00:00 weekly 0.7 https://trial.medpath.com/news/caqh-ceo-highlights-hidden-costs-and-care-gaps-in-women-s-menopausal-health 2024-12-24T08:09:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caqh-ceo-highlights-hidden-costs-and-care-gaps-in-women-s-menopausal-health 2024-12-24T08:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/the-novel-bispecific-antibody-ivonescimab-may-be-poised-to-change-the-soc-in-nsclc 2024-12-24T08:03:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-novel-bispecific-antibody-ivonescimab-may-be-poised-to-change-the-soc-in-nsclc 2024-12-24T08:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/nature-cell-seeks-fda-meeting-for-arthritis-therapy-approval-kbr 2024-12-24T08:03:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nature-cell-seeks-fda-meeting-for-arthritis-therapy-approval-kbr 2024-12-24T08:03:35+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-withdraws-eu-application-for-lung-cancer-drug-tipranks-com 2024-12-24T07:12:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-withdraws-eu-application-for-lung-cancer-drug-tipranks-com 2024-12-24T07:12:32+00:00 weekly 0.7 https://trial.medpath.com/news/anavex-life-sciences-corp-avxl-q4-2024-earnings-call-highlights-strong-cash-position-and 2024-12-24T07:05:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anavex-life-sciences-corp-avxl-q4-2024-earnings-call-highlights-strong-cash-position-and 2024-12-24T07:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/ribociclib-combo-may-provide-benefit-to-certain-breast-cancer-subtypes-oncology-nursing-news 2024-12-24T07:04:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ribociclib-combo-may-provide-benefit-to-certain-breast-cancer-subtypes-oncology-nursing-news 2024-12-24T07:04:53+00:00 weekly 0.7 https://trial.medpath.com/news/study-calls-for-optimization-of-high-cost-ivig-therapy-in-bk-nephropathy-treatment 2024-12-24T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-calls-for-optimization-of-high-cost-ivig-therapy-in-bk-nephropathy-treatment 2024-12-24T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-digitalization-transforms-drug-development-ai-remote-monitoring-and-data-ecosystems-lead-innovation 2024-12-24T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-digitalization-transforms-drug-development-ai-remote-monitoring-and-data-ecosystems-lead-innovation 2024-12-24T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-edward-kim-champions-diversity-and-innovation-in-cancer-clinical-trials-at-city-of-hope 2024-12-24T06:00:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-edward-kim-champions-diversity-and-innovation-in-cancer-clinical-trials-at-city-of-hope 2024-12-24T06:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-reveals-disparities-in-car-t-cell-therapy-outcomes-across-patient-demographics 2024-12-24T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-evidence-reveals-disparities-in-car-t-cell-therapy-outcomes-across-patient-demographics 2024-12-24T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2024-glp-1-breakthroughs-clinical-advances-and-regulatory-developments-transform-treatment-landscape 2024-12-24T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-glp-1-breakthroughs-clinical-advances-and-regulatory-developments-transform-treatment-landscape 2024-12-24T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-multi-center-open-label-randomized-clinical-trial-evaluating-the-preventive-effect-of-trials 2024-12-24T04:37:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-multi-center-open-label-randomized-clinical-trial-evaluating-the-preventive-effect-of-trials 2024-12-24T04:37:07+00:00 weekly 0.7 https://trial.medpath.com/news/new-migraine-drug-atogepant-shows-quick-relief-news-medical 2024-12-24T04:06:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-migraine-drug-atogepant-shows-quick-relief-news-medical 2024-12-24T04:06:24+00:00 weekly 0.7 https://trial.medpath.com/news/higher-sodium-intake-significantly-increases-atopic-dermatitis-risk-and-severity-uk-study-finds 2024-12-24T03:24:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/higher-sodium-intake-significantly-increases-atopic-dermatitis-risk-and-severity-uk-study-finds 2024-12-24T03:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/polypid-announces-positive-recommendation-by-dsmb-to-continue-enrollment-of-phase-3 2024-12-24T01:07:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/polypid-announces-positive-recommendation-by-dsmb-to-continue-enrollment-of-phase-3 2024-12-24T01:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/aplt-investor-alert-robbins-llp-reminds-stockholders-of-globenewswire 2024-12-24T00:32:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aplt-investor-alert-robbins-llp-reminds-stockholders-of-globenewswire 2024-12-24T00:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/who-tag-co-vac-reviews-covid-19-vaccine-effectiveness-and-antigen-composition 2024-12-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-tag-co-vac-reviews-covid-19-vaccine-effectiveness-and-antigen-composition 2024-12-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/anebulo-pharmaceuticals-advances-selonabant-development-with-fda-collaboration 2024-12-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anebulo-pharmaceuticals-advances-selonabant-development-with-fda-collaboration 2024-12-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-pharmaceuticals-price-target-lowered-to-460-from-550-at-truist 2024-12-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-price-target-lowered-to-460-from-550-at-truist 2024-12-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-transfusing-more-blood-reduces-risk-of-death-at-six-months-in-heart-attack 2024-12-23T22:09:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-finds-transfusing-more-blood-reduces-risk-of-death-at-six-months-in-heart-attack 2024-12-23T22:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/anavex-life-sciences-corp-sec-10-k-report-tradingview 2024-12-23T22:00:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anavex-life-sciences-corp-sec-10-k-report-tradingview 2024-12-23T22:00:11+00:00 weekly 0.7 https://trial.medpath.com/news/most-read-stories-from-2024-drug-topics 2024-12-23T21:51:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/most-read-stories-from-2024-drug-topics 2024-12-23T21:51:20+00:00 weekly 0.7 https://trial.medpath.com/news/biomarker-selected-treatment-shows-promise-for-bladder-preservation-in-mibc 2024-12-23T21:47:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomarker-selected-treatment-shows-promise-for-bladder-preservation-in-mibc 2024-12-23T21:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/prophylactic-tocilizumab-reduces-toxicity-boosts-efficacy-in-immune-checkpoint-inhibitor 2024-12-23T21:39:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prophylactic-tocilizumab-reduces-toxicity-boosts-efficacy-in-immune-checkpoint-inhibitor 2024-12-23T21:39:02+00:00 weekly 0.7 https://trial.medpath.com/news/avita-medical-announces-fda-approval-of-recell-go-mini-globenewswire 2024-12-23T21:11:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avita-medical-announces-fda-approval-of-recell-go-mini-globenewswire 2024-12-23T21:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/published-aspire-data-show-noninferior-stone-free-rate-with-sure-vs-urs-urology-times 2024-12-23T20:06:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/published-aspire-data-show-noninferior-stone-free-rate-with-sure-vs-urs-urology-times 2024-12-23T20:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/irox-as-second-line-therapy-for-metastatic-colorectal-cancer 2024-12-23T19:36:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/irox-as-second-line-therapy-for-metastatic-colorectal-cancer 2024-12-23T19:36:00+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-breast-cancer-breakthroughs-in-2024-targeted-oncology 2024-12-23T18:07:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-breast-cancer-breakthroughs-in-2024-targeted-oncology 2024-12-23T18:07:01+00:00 weekly 0.7 https://trial.medpath.com/news/we-ll-learn-about-ozempic-s-potential-for-alzheimer-s-disease-in-2025-new-scientist 2024-12-23T18:00:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/we-ll-learn-about-ozempic-s-potential-for-alzheimer-s-disease-in-2025-new-scientist 2024-12-23T18:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-marengo-s-invikafusp-alfa-trial-expansion-to-europe 2024-12-23T17:29:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-in-marengo-s-invikafusp-alfa-trial-expansion-to-europe 2024-12-23T17:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/medicus-pharma-ceo-charts-course-for-2025-with-clinical-milestones-for-skinject 2024-12-23T17:24:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicus-pharma-ceo-charts-course-for-2025-with-clinical-milestones-for-skinject 2024-12-23T17:24:39+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-advances-in-c-diff-vaccine-development-and-pneumococcal-shot-progress 2024-12-23T17:21:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-advances-in-c-diff-vaccine-development-and-pneumococcal-shot-progress 2024-12-23T17:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/signati-submits-de-novo-application-to-fda-after-completing-trial 2024-12-23T16:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/signati-submits-de-novo-application-to-fda-after-completing-trial 2024-12-23T16:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/chemo-free-regimen-for-ph-all-yields-high-rate-of-deep-mrd-negativity 2024-12-23T16:29:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chemo-free-regimen-for-ph-all-yields-high-rate-of-deep-mrd-negativity 2024-12-23T16:29:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-generic-of-once-daily-glp-1-injection-to-lower-blood-sugar-in-patients 2024-12-23T16:15:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-generic-of-once-daily-glp-1-injection-to-lower-blood-sugar-in-patients 2024-12-23T16:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/nvo-stock-plunges-as-obesity-drug-cagrisema-misses-target-in-phase-iii-barchart-com 2024-12-23T16:09:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nvo-stock-plunges-as-obesity-drug-cagrisema-misses-target-in-phase-iii-barchart-com 2024-12-23T16:09:58+00:00 weekly 0.7 https://trial.medpath.com/news/primary-analysis-of-zuma-2-treatment-of-btk-inhibitor-naive-relapsed-refractory-mantle 2024-12-23T16:05:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/primary-analysis-of-zuma-2-treatment-of-btk-inhibitor-naive-relapsed-refractory-mantle 2024-12-23T16:05:59+00:00 weekly 0.7 https://trial.medpath.com/news/avelumab-axitinib-vs-sunitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma 2024-12-23T15:57:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avelumab-axitinib-vs-sunitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma 2024-12-23T15:57:21+00:00 weekly 0.7 https://trial.medpath.com/news/sequoia-5-year-follow-up-zanubrutinib-vs-bendamustine-rituximab-in-treatment-naive-cll-sll 2024-12-23T15:45:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequoia-5-year-follow-up-zanubrutinib-vs-bendamustine-rituximab-in-treatment-naive-cll-sll 2024-12-23T15:45:44+00:00 weekly 0.7 https://trial.medpath.com/news/rapt-therapeutics-and-shanghai-jemincare-pharmaceutical-globenewswire 2024-12-23T15:27:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapt-therapeutics-and-shanghai-jemincare-pharmaceutical-globenewswire 2024-12-23T15:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-most-read-ipf-content-of-2024-american-journal-of-managed-care 2024-12-23T15:21:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-most-read-ipf-content-of-2024-american-journal-of-managed-care 2024-12-23T15:21:15+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-overall-survival-with-adjuvant-gemcitabine-capecitabine-vs-the-asco-post 2024-12-23T15:19:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-overall-survival-with-adjuvant-gemcitabine-capecitabine-vs-the-asco-post 2024-12-23T15:19:37+00:00 weekly 0.7 https://trial.medpath.com/news/deucravacitinib-outperforms-other-biologic-therapies-for-treatment-of-cutaneous-lupus 2024-12-23T15:15:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/deucravacitinib-outperforms-other-biologic-therapies-for-treatment-of-cutaneous-lupus 2024-12-23T15:15:54+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-tyk2-inhibitor-shows-promise-in-phase-3-psoriatic-arthritis-trials 2024-12-23T15:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-tyk2-inhibitor-shows-promise-in-phase-3-psoriatic-arthritis-trials 2024-12-23T15:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/keymed-biosciences-announces-approval-of-stapokibart-for-the-treatment-of-chronic 2024-12-23T14:53:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keymed-biosciences-announces-approval-of-stapokibart-for-the-treatment-of-chronic 2024-12-23T14:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/sumitomo-pharma-america-announces-u-s-fda-approval-of-gemtesa-r-vibegron-for 2024-12-23T14:36:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sumitomo-pharma-america-announces-u-s-fda-approval-of-gemtesa-r-vibegron-for 2024-12-23T14:36:10+00:00 weekly 0.7 https://trial.medpath.com/news/after-rejection-last-year-us-authorities-approve-new-hemophilia-drug-from-novo-nordisk 2024-12-23T14:28:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/after-rejection-last-year-us-authorities-approve-new-hemophilia-drug-from-novo-nordisk 2024-12-23T14:28:26+00:00 weekly 0.7 https://trial.medpath.com/news/xbiotech-pauses-rheumatology-program-the-manila-times 2024-12-23T14:28:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xbiotech-pauses-rheumatology-program-the-manila-times 2024-12-23T14:28:17+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-accepts-for-priority-review-nuvation-bio-s-new-biospace 2024-12-23T14:26:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-food-and-drug-administration-accepts-for-priority-review-nuvation-bio-s-new-biospace 2024-12-23T14:26:35+00:00 weekly 0.7 https://trial.medpath.com/news/axena-health-begins-patient-enrollment-for-ui-treatment-study-at-two-sites-in-nigeria 2024-12-23T14:22:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/axena-health-begins-patient-enrollment-for-ui-treatment-study-at-two-sites-in-nigeria 2024-12-23T14:22:36+00:00 weekly 0.7 https://trial.medpath.com/news/evaluation-of-bacillus-coagulans-lmg-s-31876-on-immunomodulation-and-stress-frontiers 2024-12-23T14:20:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluation-of-bacillus-coagulans-lmg-s-31876-on-immunomodulation-and-stress-frontiers 2024-12-23T14:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/most-significant-clincal-trials-of-2024 2024-12-23T14:04:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/most-significant-clincal-trials-of-2024 2024-12-23T14:04:23+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotech-s-nerlynx-secures-major-nccn-guidelines-recognition-for-cervical 2024-12-23T14:02:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotech-s-nerlynx-secures-major-nccn-guidelines-recognition-for-cervical 2024-12-23T14:02:15+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-sotyktu-phase-3-trials-in-psoriatic-arthritis-meet-primary-goals 2024-12-23T13:47:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-sotyktu-phase-3-trials-in-psoriatic-arthritis-meet-primary-goals 2024-12-23T13:47:18+00:00 weekly 0.7 https://trial.medpath.com/news/wave-life-sciences-advances-novel-obesity-drug-wve-007-targeting-inhbe-gene 2024-12-23T13:41:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wave-life-sciences-advances-novel-obesity-drug-wve-007-targeting-inhbe-gene 2024-12-23T13:41:49+00:00 weekly 0.7 https://trial.medpath.com/news/vivos-inc-announces-launch-of-groundbreaking-radiogel-r-globenewswire 2024-12-23T13:38:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vivos-inc-announces-launch-of-groundbreaking-radiogel-r-globenewswire 2024-12-23T13:38:44+00:00 weekly 0.7 https://trial.medpath.com/news/tailor-made-for-a-lifelong-pursuit-of-precision-in-cancer-care-onclive 2024-12-23T13:08:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tailor-made-for-a-lifelong-pursuit-of-precision-in-cancer-care-onclive 2024-12-23T13:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/oak-bay-kid-turns-on-the-charm-for-clinical-trials-hub-at-bc-children-s-sooke-news-mirror 2024-12-23T13:05:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oak-bay-kid-turns-on-the-charm-for-clinical-trials-hub-at-bc-children-s-sooke-news-mirror 2024-12-23T13:05:03+00:00 weekly 0.7 https://trial.medpath.com/news/signati-medical-successfully-completes-ide-trial-for-separo-vessel-sealing-system 2024-12-23T13:02:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/signati-medical-successfully-completes-ide-trial-for-separo-vessel-sealing-system 2024-12-23T13:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/cosciens-biopharma-inc-provides-corporate-update-and-highlights-pipeline-prioritization 2024-12-23T12:58:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cosciens-biopharma-inc-provides-corporate-update-and-highlights-pipeline-prioritization 2024-12-23T12:58:46+00:00 weekly 0.7 https://trial.medpath.com/news/gain-therapeutics-advances-parkinson-s-treatment-phase-1b-trial-approved-after-stock-titan 2024-12-23T12:41:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gain-therapeutics-advances-parkinson-s-treatment-phase-1b-trial-approved-after-stock-titan 2024-12-23T12:41:41+00:00 weekly 0.7 https://trial.medpath.com/news/telomir-s-breakthrough-drug-shows-promise-for-wilson-s-disease-as-company-expands 2024-12-23T12:41:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/telomir-s-breakthrough-drug-shows-promise-for-wilson-s-disease-as-company-expands 2024-12-23T12:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/glaukos-submits-new-drug-application-to-u-s-fda-for-epioxa-stock-titan 2024-12-23T12:22:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glaukos-submits-new-drug-application-to-u-s-fda-for-epioxa-stock-titan 2024-12-23T12:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/traws-pharma-announces-progress-in-developing-tivoxavir-marboxil-for-h5n1-bird-flu 2024-12-23T12:18:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/traws-pharma-announces-progress-in-developing-tivoxavir-marboxil-for-h5n1-bird-flu 2024-12-23T12:18:15+00:00 weekly 0.7 https://trial.medpath.com/news/eu-approves-opdivo-yervoy-combo-for-colorectal-cancer-investing-com 2024-12-23T12:07:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-approves-opdivo-yervoy-combo-for-colorectal-cancer-investing-com 2024-12-23T12:07:37+00:00 weekly 0.7 https://trial.medpath.com/news/protalix-biotherapeutics-issues-2025-letter-to-stockholders-stock-titan 2024-12-23T12:02:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protalix-biotherapeutics-issues-2025-letter-to-stockholders-stock-titan 2024-12-23T12:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/study-unveils-nad-s-link-to-aging-and-disease-development-news-medical 2024-12-23T12:01:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-unveils-nad-s-link-to-aging-and-disease-development-news-medical 2024-12-23T12:01:58+00:00 weekly 0.7 https://trial.medpath.com/news/novel-3d-osteosarcoma-spheroid-models-show-promise-for-enhanced-preclinical-drug-testing 2024-12-23T12:00:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-3d-osteosarcoma-spheroid-models-show-promise-for-enhanced-preclinical-drug-testing 2024-12-23T12:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-significant-racial-and-mental-health-disparities-in-alopecia-areata-patients 2024-12-23T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-significant-racial-and-mental-health-disparities-in-alopecia-areata-patients 2024-12-23T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/zura-bio-launches-groundbreaking-phase-2-trial-for-novel-dual-pathway-autoimmune-treatment 2024-12-23T11:48:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zura-bio-launches-groundbreaking-phase-2-trial-for-novel-dual-pathway-autoimmune-treatment 2024-12-23T11:48:08+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-nv-387-shows-breakthrough-88-survival-rate-against-h5n1-bird-flu-in-key-study 2024-12-23T11:38:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoviricides-nv-387-shows-breakthrough-88-survival-rate-against-h5n1-bird-flu-in-key-study 2024-12-23T11:38:55+00:00 weekly 0.7 https://trial.medpath.com/news/prediction-of-metabolic-subphenotypes-of-type-2-diabetes-via-continuous-glucose-monitoring 2024-12-23T10:36:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prediction-of-metabolic-subphenotypes-of-type-2-diabetes-via-continuous-glucose-monitoring 2024-12-23T10:36:31+00:00 weekly 0.7 https://trial.medpath.com/news/pig-kidney-transplants-new-schizophrenia-drug-here-are-5-of-the-biggest-medical-abc-news 2024-12-23T10:28:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pig-kidney-transplants-new-schizophrenia-drug-here-are-5-of-the-biggest-medical-abc-news 2024-12-23T10:28:58+00:00 weekly 0.7 https://trial.medpath.com/news/nexalin-technology-advances-with-phase-1-completion-of-virtual-clinic-for-brain-stimulation-therapy 2024-12-23T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nexalin-technology-advances-with-phase-1-completion-of-virtual-clinic-for-brain-stimulation-therapy 2024-12-23T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/effects-of-two-different-dexamethasone-dosing-regimens-on-ventilator-free-days-and-long 2024-12-23T09:47:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effects-of-two-different-dexamethasone-dosing-regimens-on-ventilator-free-days-and-long 2024-12-23T09:47:22+00:00 weekly 0.7 https://trial.medpath.com/news/preclinical-evaluation-of-bavdegalutamide-arv-110-a-novel-proteolysis-targeting 2024-12-23T09:23:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/preclinical-evaluation-of-bavdegalutamide-arv-110-a-novel-proteolysis-targeting 2024-12-23T09:23:09+00:00 weekly 0.7 https://trial.medpath.com/news/biophytis-showcased-the-oba-program-in-obesity-at-the-17th-scwd-international-congress 2024-12-23T09:12:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biophytis-showcased-the-oba-program-in-obesity-at-the-17th-scwd-international-congress 2024-12-23T09:12:46+00:00 weekly 0.7 https://trial.medpath.com/news/molecular-testing-emerges-as-critical-factor-in-nsclc-treatment-decision-making 2024-12-23T09:11:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/molecular-testing-emerges-as-critical-factor-in-nsclc-treatment-decision-making 2024-12-23T09:11:51+00:00 weekly 0.7 https://trial.medpath.com/news/vivozon-pharmaceutical-to-launch-unafra-as-a-new-surgical-painkiller-market-in-h2-2025 2024-12-23T08:53:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vivozon-pharmaceutical-to-launch-unafra-as-a-new-surgical-painkiller-market-in-h2-2025 2024-12-23T08:53:04+00:00 weekly 0.7 https://trial.medpath.com/news/nationwide-recall-unapproved-epinephrine-nasal-solution-raises-safety-concerns 2024-12-23T08:50:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nationwide-recall-unapproved-epinephrine-nasal-solution-raises-safety-concerns 2024-12-23T08:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/vittoria-biotherapeutics-doses-first-patient-in-phase-1-clinical-trial-of-viper-101 2024-12-23T07:32:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vittoria-biotherapeutics-doses-first-patient-in-phase-1-clinical-trial-of-viper-101 2024-12-23T07:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/usfda-gives-orphan-drug-designation-and-rare-paediatric-disease-biospectrum-asia 2024-12-23T07:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/usfda-gives-orphan-drug-designation-and-rare-paediatric-disease-biospectrum-asia 2024-12-23T07:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/tagrisso-approved-in-the-eu-for-patients-with-unresectable-egfr-mutated-lung-cancer 2024-12-23T07:05:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tagrisso-approved-in-the-eu-for-patients-with-unresectable-egfr-mutated-lung-cancer 2024-12-23T07:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/exercise-shows-promise-in-managing-chemotherapy-induced-neuropathy-for-ovarian-cancer-patients 2024-12-23T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exercise-shows-promise-in-managing-chemotherapy-induced-neuropathy-for-ovarian-cancer-patients 2024-12-23T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-sequana-medical-announces-us-fda-approval-of-globenewswire 2024-12-23T06:21:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-sequana-medical-announces-us-fda-approval-of-globenewswire 2024-12-23T06:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/ellipses-launches-pioneering-clinical-trial-programme-in-middle-east-morningstar 2024-12-23T06:16:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ellipses-launches-pioneering-clinical-trial-programme-in-middle-east-morningstar 2024-12-23T06:16:55+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-sanofi-initiates-phase-3-program-for-pcv21-globenewswire 2024-12-23T06:03:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-sanofi-initiates-phase-3-program-for-pcv21-globenewswire 2024-12-23T06:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/5-companies-that-celebrated-first-approvals-in-2024-biospace 2024-12-23T05:17:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-companies-that-celebrated-first-approvals-in-2024-biospace 2024-12-23T05:17:08+00:00 weekly 0.7 https://trial.medpath.com/news/2024-highlights-the-rollercoaster-that-is-neuro-biospace 2024-12-23T05:09:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-highlights-the-rollercoaster-that-is-neuro-biospace 2024-12-23T05:09:35+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-in-nsclc-experts-address-patient-selection-and-access-challenges 2024-12-23T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-in-nsclc-experts-address-patient-selection-and-access-challenges 2024-12-23T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-cultural-and-spiritual-factors-impact-post-mastectomy-decisions-in-women-of-color 2024-12-23T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-cultural-and-spiritual-factors-impact-post-mastectomy-decisions-in-women-of-color 2024-12-23T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dextromethorphan-found-to-have-potential-in-treating-lung-fibrosis-news-medical 2024-12-23T04:35:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dextromethorphan-found-to-have-potential-in-treating-lung-fibrosis-news-medical 2024-12-23T04:35:50+00:00 weekly 0.7 https://trial.medpath.com/news/aua-2024-breakthrough-developments-in-male-contraception-bladder-cancer-treatment-and-health-equity-initiatives 2024-12-23T04:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aua-2024-breakthrough-developments-in-male-contraception-bladder-cancer-treatment-and-health-equity-initiatives 2024-12-23T04:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/kinoxis-secures-2-5m-grant-for-dementia-agitation-treatment-clinical-trial-inside-ageing 2024-12-23T03:35:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kinoxis-secures-2-5m-grant-for-dementia-agitation-treatment-clinical-trial-inside-ageing 2024-12-23T03:35:31+00:00 weekly 0.7 https://trial.medpath.com/news/top-oncology-healthcare-trends-of-2024-prior-authorization-pbm-reform-and-patient-navigation-lead-discussion 2024-12-23T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-oncology-healthcare-trends-of-2024-prior-authorization-pbm-reform-and-patient-navigation-lead-discussion 2024-12-23T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/application-of-indocyanine-green-human-serum-albumin-complex-in-fluorescence-image-trials 2024-12-23T02:31:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/application-of-indocyanine-green-human-serum-albumin-complex-in-fluorescence-image-trials 2024-12-23T02:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/celltrion-s-actemra-biosimilar-wins-approval-in-korea-bio-article-kbr 2024-12-23T02:09:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celltrion-s-actemra-biosimilar-wins-approval-in-korea-bio-article-kbr 2024-12-23T02:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/gi-innovation-completes-1st-patient-dosing-of-subcutaneous-immunotherapy-potentially-for-melanoma 2024-12-23T01:51:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gi-innovation-completes-1st-patient-dosing-of-subcutaneous-immunotherapy-potentially-for-melanoma 2024-12-23T01:51:44+00:00 weekly 0.7 https://trial.medpath.com/news/regarding-the-approval-of-the-additional-indication-for-endometriosis-in-europe-kituseiyao-pin-gong-ye 2024-12-23T01:27:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regarding-the-approval-of-the-additional-indication-for-endometriosis-in-europe-kituseiyao-pin-gong-ye 2024-12-23T01:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/daily-hong-kong-stock-market-news-briefing-december-23-monday-longport 2024-12-23T01:19:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daily-hong-kong-stock-market-news-briefing-december-23-monday-longport 2024-12-23T01:19:50+00:00 weekly 0.7 https://trial.medpath.com/news/ai-clinical-trials-hit-record-numbers-in-2024-as-pharma-giants-embrace-technology 2024-12-23T01:03:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-clinical-trials-hit-record-numbers-in-2024-as-pharma-giants-embrace-technology 2024-12-23T01:03:50+00:00 weekly 0.7 https://trial.medpath.com/news/cstone-announces-submission-of-clinical-trial-application-in-australia-for-cs2009-pr-newswire 2024-12-23T00:07:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cstone-announces-submission-of-clinical-trial-application-in-australia-for-cs2009-pr-newswire 2024-12-23T00:07:55+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-receptor-agonists-show-lower-risk-for-mace-and-vte-in-lupus-and-type-2-diabetes-patients-compared-to-dpp4-inhibitors 2024-12-23T00:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-show-lower-risk-for-mace-and-vte-in-lupus-and-type-2-diabetes-patients-compared-to-dpp4-inhibitors 2024-12-23T00:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/reviva-pharmaceuticals-reports-promising-preliminary-ole-data-for-brilaroxazine 2024-12-23T00:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reviva-pharmaceuticals-reports-promising-preliminary-ole-data-for-brilaroxazine 2024-12-23T00:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncolytics-biotech-inc-anticipates-key-clinical-data-readouts-in-2025 2024-12-23T00:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncolytics-biotech-inc-anticipates-key-clinical-data-readouts-in-2025 2024-12-23T00:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/sun-pharma-acquires-concert-pharmaceuticals-to-advance-alopecia-areata-treatment 2024-12-23T00:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sun-pharma-acquires-concert-pharmaceuticals-to-advance-alopecia-areata-treatment 2024-12-23T00:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-trigeminal-neuralgia-clinical-trials-2024-studies-power 2024-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-trigeminal-neuralgia-clinical-trials-2024-studies-power 2024-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/respiratory-syncytial-virus-rsv-vaccine-safety 2024-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/respiratory-syncytial-virus-rsv-vaccine-safety 2024-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2024s-top-12-clinical-trials-cromos-pharma 2024-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024s-top-12-clinical-trials-cromos-pharma 2024-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/prescient-therapeutics-gains-fda-approval-for-ptx-100-trial-tipranks-com 2024-12-22T23:51:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prescient-therapeutics-gains-fda-approval-for-ptx-100-trial-tipranks-com 2024-12-22T23:51:50+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-type-1-diabetes-therapy-autologous-islet-transplant-breakthrough-nature 2024-12-22T23:11:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancing-type-1-diabetes-therapy-autologous-islet-transplant-breakthrough-nature 2024-12-22T23:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/biowire-weekly-025-by-david-kingsley-phd-substack 2024-12-22T23:06:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biowire-weekly-025-by-david-kingsley-phd-substack 2024-12-22T23:06:11+00:00 weekly 0.7 https://trial.medpath.com/news/jhaveri-compares-safety-and-duration-of-adjuvant-cdk4-6-inhibitors-in-hr-breast-cancer 2024-12-22T20:07:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jhaveri-compares-safety-and-duration-of-adjuvant-cdk4-6-inhibitors-in-hr-breast-cancer 2024-12-22T20:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/curateq-biologics-receives-approval-for-oncology-biosimilar-bevqolva-from-uk-s-mhra 2024-12-22T18:49:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curateq-biologics-receives-approval-for-oncology-biosimilar-bevqolva-from-uk-s-mhra 2024-12-22T18:49:30+00:00 weekly 0.7